Activation-induced	O
down-regulation	O
of	O
retinoid	B-protein
receptor	I-protein
RXRalpha	I-protein
expression	O
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

Role	O
of	O
cell	O
cycle	O
regulation	O
.	O

A	O
5.4-kilobase	B-RNA
mRNA	I-RNA
,	O
the	O
expression	O
of	O
which	O
is	O
down-regulated	O
after	O
treatment	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMCs	B-cell_type
)	O
with	O
various	O
T	O
cell-activating	O
agents	O
,	O
was	O
isolated	O
using	O
an	O
mRNA	O
differential	O
display	O
method	O
.	O

Nucleotide	O
sequence	O
analysis	O
identified	O
the	O
5	B-RNA
'	I-RNA
end	I-RNA
of	O
this	O
RNA	B-RNA
as	O
human	B-RNA
retinoid	I-RNA
receptor	I-RNA
RXRalpha	I-RNA
mRNA	I-RNA
.	O

Here	O
,	O
we	O
report	O
the	O
nucleotide	O
sequence	O
of	O
3.6	B-DNA
kilobases	I-DNA
of	O
this	O
RNA	O
,	O
which	O
represents	O
the	O
3	B-RNA
'	I-RNA
end	I-RNA
of	O
RXRalpha	B-RNA
mRNA	I-RNA
,	O
the	O
sequence	O
of	O
which	O
has	O
not	O
been	O
previously	O
described	O
.	O

Activated	O
PBMCs	B-cell_type
also	O
expressed	O
lower	O
levels	O
of	O
RXRalpha	B-protein
protein	O
,	O
and	O
a	O
DNA	O
binding	O
assay	O
showed	O
that	O
the	O
activation-induced	O
loss	O
of	O
RXRalpha	B-RNA
mRNA	I-RNA
and	O
protein	O
expression	O
correlated	O
with	O
the	O
loss	O
of	O
DNA	O
binding	O
activity	O
of	O
this	O
protein	O
.	O

We	O
present	O
evidence	O
that	O
the	O
transition	O
from	O
G0/G1	O
to	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
results	O
in	O
the	O
down-regulation	O
of	O
RXRalpha	B-protein
expression	O
and	O
that	O
cell	O
cycle	O
inhibitors	O
,	O
which	O
block	O
the	O
cells	O
in	O
G1	O
phase	O
,	O
prevent	O
this	O
down-regulation	O
.	O

The	O
decrease	O
in	O
the	O
levels	O
of	O
RXRalpha	B-RNA
mRNA	I-RNA
was	O
found	O
to	O
be	O
regulated	O
at	O
the	O
post-transcriptional	O
level	O
and	O
involved	O
new	O
protein	O
synthesis	O
.	O

These	O
observations	O
indicate	O
that	O
the	O
levels	O
of	O
RXRalpha	B-protein
expression	O
in	O
T	O
lymphocytes	O
are	O
coupled	O
to	O
cell	O
cycle	O
progression	O
,	O
and	O
there	O
is	O
tight	O
regulatory	O
control	O
of	O
RXRalpha	B-protein
expression	O
during	O
the	O
transition	O
from	O
G0/G1	O
to	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

THE	NULL
JOURNAL	NULL
or	NULL
BIOLOGICAL	NULL
CHEMISTRY	NULL
Vol	NULL
.	NULL

273	NULL
,	NULL
No	NULL
.	NULL

33	NULL
,	NULL
Issue	NULL
of	NULL
August	NULL
14	NULL
,	NULL
pp	NULL
.	NULL

21210-21216	NULL
,	NULL
1998	NULL
Printed	NULL
in	NULL
U.S.A.	NULL
Activation-induced	NULL
Down-regulation	NULL
of	NULL
Retinoid	NULL
Receptor	NULL
RXRa	NULL
Expression	NULL
in	NULL
Human	NULL
T	NULL
Lymphocytes	NULL
ROLE	NULL
OF	NULL
CELL	NULL
CYCLE	NULL
REGULATION®*	NULL
(	NULL
Received	NULL
for	NULL
publication	NULL
,	NULL
February	NULL
10	NULL
,	NULL
1998	NULL
,	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
,	NULL
June	NULL
5	NULL
,	NULL
1998	NULL
)	NULL
Mohammad	NULL
Ishaqt	NULL
$	NULL
§	NULL
,	NULL
Yi-Ming	NULL
Zhang	NULL
'	NULL
1	NULL
,	NULL
and	NULL
Ven	NULL
Natarajan	NULL
}	NULL
From	NULL
the	NULL
{	NULL
Laboratory	NULL
of	NULL
Molecular	NULL
Cell	NULL
Biology	NULL
and	NULL
the	NULL
Laboratory	NULL
of	NULL
Molecular	NULL
Retrovirology	NULL
,	NULL
SAIC-Frederick	NULL
,	NULL
National	NULL
Cancer	NULL
Institute-Frederick	NULL
Cancer	NULL
Research	NULL
and	NULL
Development	NULL
Center	NULL
,	NULL
Frederick	NULL
,	NULL
Maryland	NULL
21702-1201	NULL
A	NULL
5.4-kilobase	NULL
mRNA	NULL
,	NULL
the	NULL
expression	NULL
of	NULL
which	NULL
is	NULL
down-regulated	NULL
after	NULL
treatment	NULL
of	NULL
human	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
PBMCs	NULL
)	NULL
with	NULL
various	NULL
T	NULL
cell-activating	NULL
agents	NULL
,	NULL
was	NULL
isolated	NULL
using	NULL
an	NULL
mRNA	NULL
differential	NULL
display	NULL
method	NULL
.	NULL

Nucleotide	NULL
sequence	NULL
analysis	NULL
identified	NULL
the	NULL
5	NULL
'	NULL
end	NULL
of	NULL
this	NULL
RNA	NULL
as	NULL
human	NULL
retinoid	NULL
receptor	NULL
RXRa	NULL
mRNA	NULL
.	NULL

Here	NULL
,	NULL
we	NULL
report	NULL
the	NULL
nucleotide	NULL
sequence	NULL
of	NULL
3.6	NULL
kilobases	NULL
of	NULL
this	NULL
RNA	NULL
,	NULL
which	NULL
represents	NULL
the	NULL
3	NULL
'	NULL
end	NULL
of	NULL
RXRa	NULL
mRNA	NULL
,	NULL
the	NULL
sequence	NULL
of	NULL
which	NULL
has	NULL
not	NULL
been	NULL
previously	NULL
described	NULL
.	NULL

Activated	NULL
PBMCs	NULL
also	NULL
expressed	NULL
lower	NULL
levels	NULL
of	NULL
RXRa	NULL
protein	NULL
,	NULL
and	NULL
a	NULL
DNA	NULL
binding	NULL
assay	NULL
showed	NULL
that	NULL
the	NULL
activation-induced	NULL
loss	NULL
of	NULL
RXRa	NULL
mRNA	NULL
and	NULL
protein	NULL
expression	NULL
correlated	NULL
with	NULL
the	NULL
loss	NULL
of	NULL
DNA	NULL
binding	NULL
activity	NULL
of	NULL
this	NULL
protein	NULL
.	NULL

We	NULL
present	NULL
evidence	NULL
that	NULL
the	NULL
transition	NULL
from	NULL
G/G	NULL
,	NULL
to	NULL
S	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
results	NULL
in	NULL
the	NULL
down-regulation	NULL
of	NULL
RXRa	NULL
expression	NULL
and	NULL
that	NULL
cell	NULL
cycle	NULL
inhibitors	NULL
,	NULL
which	NULL
block	NULL
the	NULL
cells	NULL
in	NULL
G	NULL
,	NULL
phase	NULL
,	NULL
prevent	NULL
this	NULL
down-regulation	NULL
.	NULL

The	NULL
decrease	NULL
in	NULL
the	NULL
levels	NULL
of	NULL
RXRa	NULL
mRNA	NULL
was	NULL
found	NULL
to	NULL
be	NULL
regulated	NULL
at	NULL
the	NULL
post-transcriptional	NULL
level	NULL
and	NULL
involved	NULL
new	NULL
protein	NULL
synthe-sis	NULL
.	NULL

These	NULL
observations	NULL
indicate	NULL
that	NULL
the	NULL
levels	NULL
of	NULL
RXRa	NULL
expression	NULL
in	NULL
T	NULL
lymphocytes	NULL
are	NULL
coupled	NULL
to	NULL
cell	NULL
cycle	NULL
progression	NULL
,	NULL
and	NULL
there	NULL
is	NULL
tight	NULL
regulatory	NULL
control	NULL
of	NULL
RXRa	NULL
expression	NULL
during	NULL
the	NULL
transition	NULL
from	NULL
G/G	NULL
,	NULL
to	NULL
S	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

During	NULL
the	NULL
physiological	NULL
response	NULL
to	NULL
antigens	NULL
,	NULL
T	NULL
cells	NULL
are	NULL
activated	NULL
through	NULL
the	NULL
interaction	NULL
of	NULL
the	NULL
processed	NULL
antigen	NULL
with	NULL
the	NULL
TCR-CD3	NULL
complex	NULL
,	NULL
resulting	NULL
in	NULL
a	NULL
complex	NULL
signaling	NULL
pathway	NULL
that	NULL
culminates	NULL
in	NULL
cellular	NULL
proliferation	NULL
and	NULL
a	NULL
specific	NULL
immune	NULL
response	NULL
.	NULL

The	NULL
activation	NULL
of	NULL
T	NULL
cells	NULL
is	NULL
a	NULL
highly	NULL
regulated	NULL
process	NULL
,	NULL
which	NULL
involves	NULL
transcriptional	NULL
control	NULL
of	NULL
many	NULL
genes	NULL
(	NULL
1	NULL
)	NULL
.	NULL

Among	NULL
the	NULL
well	NULL
characterized	NULL
pathways	NULL
of	NULL
TCR	NULL
!	NULL

*	NULL
This	NULL
project	NULL
has	NULL
been	NULL
funded	NULL
with	NULL
federal	NULL
funds	NULL
from	NULL
the	NULL
Department	NULL
of	NULL
Health	NULL
and	NULL
Human	NULL
Services	NULL
under	NULL
contract	NULL
number	NULL
NO1-CO-5600	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1784	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

The	NULL
nucleotide	NULL
sequence	NULL
(	NULL
s	NULL
)	NULL
reported	NULL
in	NULL
this	NULL
paper	NULL
has	NULL
been	NULL
submitted	NULL
to	NULL
the	NULL
GenBank	NULL
``	NULL
``	NULL
/	NULL
EBI	NULL
Data	NULL
Bank	NULL
with	NULL
accession	NULL
number	NULL
(	NULL
s	NULL
)	NULL
U66306	NULL
.	NULL

§	NULL
To	NULL
whom	NULL
correspondence	NULL
should	NULL
be	NULL
addressed	NULL
.	NULL

Tel	NULL
.	NULL

:	NULL
301-846-1910	NULL
;	NULL
Fax	NULL
:	NULL
301-846-6762	NULL
.	NULL

*	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
TCR	NULL
,	NULL
T	NULL
cell	NULL
receptor	NULL
;	NULL
PBMC	NULL
,	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cell	NULL
;	NULL
DD-RT-PCR	NULL
,	NULL
differential	NULL
display	NULL
reverse	NULL
transcription	NULL
polymerase	NULL
chain	NULL
reaction	NULL
;	NULL
RAR	NULL
,	NULL
retinoic	NULL
acid	NULL
receptor	NULL
;	NULL
RXR	NULL
,	NULL
retinoid	NULL
X	NULL
receptor	NULL
;	NULL
RACE	NULL
,	NULL
rapid	NULL
amplification	NULL
of	NULL
cDNA	NULL
ends	NULL
;	NULL
ION	NULL
,	NULL
ionomycin	NULL
;	NULL
RAP	NULL
,	NULL
rapamycin	NULL
;	NULL
CsA	NULL
,	NULL
cyclosporin	NULL
A	NULL
;	NULL
PMA	NULL
,	NULL
phorbol	NULL
12-myristate	NULL
18-acetate	NULL
;	NULL
PHA	NULL
,	NULL
phytohemagglutininy	NULL
EMSA	NULL
,	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
;	NULL
PBS	NULL
,	NULL
phosphate-buffered	NULL
saline	NULL
;	NULL
Act	NULL
D	NULL
,	NULL
actinomycin	NULL
D	NULL
;	NULL
CHX	NULL
,	NULL
cycloheximide	NULL
;	NULL
kb	NULL
,	NULL
kilobase	NULL
(	NULL
s	NULL
)	NULL
;	NULL
MOPS	NULL
,	NULL
4-morpho-linepropanesulfonic	NULL
acid	NULL
;	NULL
GAPDH	NULL
,	NULL
glyceraldehyde-3-phosphate	NULL
dehy-drogenase	NULL
;	NULL
IL2	NULL
,	NULL
interleukin	NULL
2	NULL
;	NULL
ConA	NULL
,	NULL
concanavalin	NULL
A	NULL
.	NULL

21210	NULL
signaling	NULL
are	NULL
the	NULL
activation	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
and	NULL
the	NULL
increase	NULL
in	NULL
the	NULL
intracellular	NULL
calcium	NULL
levels	NULL
(	NULL
2	NULL
,	NULL
3	NULL
)	NULL
,	NULL
both	NULL
of	NULL
which	NULL
are	NULL
involved	NULL
in	NULL
the	NULL
transcriptional	NULL
control	NULL
of	NULL
several	NULL
genes	NULL
.	NULL

The	NULL
genes	NULL
that	NULL
are	NULL
activated	NULL
early	NULL
in	NULL
T	NULL
cell	NULL
activation	NULL
include	NULL
IL2	NULL
,	NULL
IL2	NULL
receptor	NULL
,	NULL
and	NULL
the	NULL
proto-oncogenes	NULL
c-fos	NULL
and	NULL
c-myc	NULL
(	NULL
1	NULL
)	NULL
.	NULL

Antibodies	NULL
against	NULL
a	NULL
number	NULL
of	NULL
T	NULL
cell	NULL
surface	NULL
molecules	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
induce	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

Among	NULL
these	NULL
are	NULL
CD3	NULL
,	NULL
TCR	NULL
«	NULL
B	NULL
,	NULL
CD2	NULL
,	NULL
Thy-1	NULL
,	NULL
and	NULL
Ly-6	NULL
(	NULL
4-9	NULL
)	NULL
.	NULL

The	NULL
activation	NULL
of	NULL
resting	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
by	NULL
TCR-CD3	NULL
ligation	NULL
can	NULL
be	NULL
mimicked	NULL
by	NULL
treatment	NULL
with	NULL
phorbol	NULL
myristate	NULL
and	NULL
ionomycin	NULL
(	NULL
ION	NULL
)	NULL
,	NULL
which	NULL
induce	NULL
protein	NULL
kinase	NULL
C	NULL
activation	NULL
and	NULL
an	NULL
increase	NULL
in	NULL
the	NULL
intracellular	NULL
calcium	NULL
pool	NULL
(	NULL
10	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
lectins	NULL
like	NULL
phyto-hemagglutinin	NULL
(	NULL
PHA	NULL
)	NULL
or	NULL
concanavalin	NULL
A	NULL
can	NULL
induce	NULL
T	NULL
cell	NULL
activation	NULL
in	NULL
normal	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
(	NULL
9	NULL
)	NULL
.	NULL

Retinoid	NULL
X	NULL
receptors	NULL
(	NULL
RXRs	NULL
)	NULL
and	NULL
retinoic	NULL
acid	NULL
receptors	NULL
(	NULL
RARs	NULL
)	NULL
are	NULL
a	NULL
group	NULL
of	NULL
nuclear	NULL
receptors	NULL
involved	NULL
in	NULL
retinoic	NULL
acid-mediated	NULL
gene	NULL
activation	NULL
(	NULL
11	NULL
,	NULL
12	NULL
)	NULL
.	NULL

After	NULL
ligand	NULL
binding	NULL
,	NULL
these	NULL
receptors	NULL
exert	NULL
their	NULL
action	NULL
by	NULL
binding	NULL
,	NULL
as	NULL
homodimers	NULL
or	NULL
heterodimers	NULL
,	NULL
to	NULL
specific	NULL
sequences	NULL
in	NULL
the	NULL
promoters	NULL
of	NULL
target	NULL
genes	NULL
and	NULL
regulate	NULL
their	NULL
transcription	NULL
.	NULL

Retinoid	NULL
receptor	NULL
functions	NULL
can	NULL
also	NULL
be	NULL
mediated	NULL
by	NULL
a	NULL
pathway	NULL
that	NULL
does	NULL
not	NULL
require	NULL
receptor-DNA	NULL
interaction	NULL
.	NULL

This	NULL
mechanism	NULL
involves	NULL
interaction	NULL
of	NULL
nuclear	NULL
receptors	NULL
and	NULL
the	NULL
transcription	NULL
factor	NULL
AP-1	NULL
(	NULL
c-Jun/c-Fos	NULL
)	NULL
,	NULL
which	NULL
results	NULL
in	NULL
the	NULL
inhibition	NULL
of	NULL
AP-1	NULL
activity	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Recent	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
retinoic	NULL
acid	NULL
inhibits	NULL
activation-induced	NULL
apoptosis	NULL
in	NULL
T	NULL
cell	NULL
hybridomas	NULL
and	NULL
thymo-cytes	NULL
,	NULL
and	NULL
RXRs	NULL
may	NULL
have	NULL
a	NULL
role	NULL
in	NULL
this	NULL
protection	NULL
(	NULL
14-17	NULL
)	NULL
.	NULL

To	NULL
understand	NULL
the	NULL
molecular	NULL
basis	NULL
of	NULL
T	NULL
cell	NULL
activation	NULL
,	NULL
the	NULL
analysis	NULL
of	NULL
changes	NULL
in	NULL
gene	NULL
expression	NULL
after	NULL
activation	NULL
is	NULL
of	NULL
prime	NULL
importance	NULL
.	NULL

We	NULL
are	NULL
interested	NULL
in	NULL
the	NULL
identification	NULL
of	NULL
genes	NULL
that	NULL
are	NULL
involved	NULL
in	NULL
T	NULL
cell	NULL
activation	NULL
,	NULL
proliferation	NULL
,	NULL
and	NULL
cell	NULL
death	NULL
.	NULL

A	NULL
recently	NULL
described	NULL
PCR-based	NULL
method	NULL
called	NULL
differential	NULL
display	NULL
PCR	NULL
(	NULL
18	NULL
,	NULL
19	NULL
)	NULL
has	NULL
been	NULL
used	NULL
to	NULL
isolate	NULL
genes	NULL
and	NULL
study	NULL
their	NULL
differential	NULL
expression	NULL
(	NULL
20-22	NULL
)	NULL
.	NULL

In	NULL
this	NULL
report	NULL
using	NULL
differential	NULL
display	NULL
reverse	NULL
transcription	NULL
polymerase	NULL
chain	NULL
reaction	NULL
(	NULL
DD-RT-PCR	NULL
)	NULL
,	NULL
we	NULL
describe	NULL
the	NULL
isolation	NULL
of	NULL
an	NULL
approximately	NULL
5.4-kb	NULL
mRNA	NULL
from	NULL
human	NULL
PBMCs	NULL
,	NULL
the	NULL
expression	NULL
of	NULL
which	NULL
is	NULL
down-regulated	NULL
after	NULL
treatment	NULL
of	NULL
PBMCs	NULL
or	NULL
purified	NULL
T	NULL
lymphocytes	NULL
with	NULL
various	NULL
T	NULL
cell-activating	NULL
agents	NULL
.	NULL

Nucleotide	NULL
sequence	NULL
analysis	NULL
reveals	NULL
that	NULL
the	NULL
5	NULL
end	NULL
of	NULL
this	NULL
mRNA	NULL
(	NULL
approximately	NULL
1.8	NULL
kb	NULL
)	NULL
is	NULL
homologous	NULL
to	NULL
the	NULL
published	NULL
sequences	NULL
of	NULL
human	NULL
RXRa	NULL
,	NULL
and	NULL
the	NULL
3	NULL
'	NULL
end	NULL
(	NULL
approximately	NULL
3.6	NULL
kb	NULL
)	NULL
does	NULL
not	NULL
match	NULL
any	NULL
sequences	NULL
in	NULL
the	NULL
GenBank	NULL
except	NULL
some	NULL
expressed	NULL
sequence	NULL
tags	NULL
.	NULL

We	NULL
show	NULL
that	NULL
this	NULL
3.6-kb	NULL
sequence	NULL
represents	NULL
the	NULL
3	NULL
'	NULL
end	NULL
of	NULL
the	NULL
human	NULL
RXRa	NULL
mRNA	NULL
,	NULL
the	NULL
sequence	NULL
of	NULL
which	NULL
has	NULL
not	NULL
been	NULL
previously	NULL
reported	NULL
in	NULL
the	NULL
literature	NULL
.	NULL

We	NULL
also	NULL
provide	NULL
evidence	NULL
that	NULL
the	NULL
activation-induced	NULL
down-regulation	NULL
of	NULL
expression	NULL
of	NULL
RXRa	NULL
«	NULL
can	NULL
be	NULL
prevented	NULL
by	NULL
treatments	NULL
that	NULL
block	NULL
cells	NULL
in	NULL
G	NULL
,	NULL
phase	NULL
and	NULL
prevent	NULL
activation	NULL
and	NULL
transition	NULL
into	NULL
the	NULL
S	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
,	NULL
indicating	NULL
cell	NULL
cycle	NULL
regulation	NULL
of	NULL
RXRa	NULL
expression	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

This	NULL
paper	NULL
is	NULL
available	NULL
on	NULL
line	NULL
at	NULL
http	NULL
:	NULL
//www.jbc.org	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
Activation-induced	NULL
RXRa	NULL
Down-regulation	NULL
in	NULL
T	NULL
Lymphocytes	NULL
EXPERIMENTAL	NULL
PROCEDURES	NULL
Cells	NULL
and	NULL
Treatments-Human	NULL
PBMCs	NULL
obtained	NULL
by	NULL
lymphapheresis	NULL
of	NULL
healthy	NULL
donors	NULL
were	NULL
purified	NULL
by	NULL
Histopaque	NULL
(	NULL
Sigma	NULL
)	NULL
density	NULL
gradient	NULL
centrifugation	NULL
.	NULL

PBMCs	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
medium	NULL
(	NULL
Biowhi-taker	NULL
,	NULL
Frederick	NULL
,	NULL
MD	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
mM	NULL
HEPES	NULL
buffer	NULL
,	NULL
2	NULL
mM	NULL
L-glutamine	NULL
,	NULL
60	NULL
ug/ml	NULL
gentamicin	NULL
,	NULL
and	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Inc.	NULL
)	NULL
.	NULL

CD4*	NULL
and	NULL
CD8*	NULL
T	NULL
lymphocytes	NULL
were	NULL
isolated	NULL
using	NULL
Dynal	NULL
beads	NULL
(	NULL
Dynal	NULL
,	NULL
Oslo	NULL
,	NULL
Norway	NULL
)	NULL
.	NULL

The	NULL
resulting	NULL
cell	NULL
populations	NULL
were	NULL
greater	NULL
than	NULL
97	NULL
%	NULL
CDS3-positive	NULL
as	NULL
monitored	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

Cells	NULL
(	NULL
10	NULL
%	NULL
/ml	NULL
)	NULL
were	NULL
treated	NULL
with	NULL
OKT3	NULL
(	NULL
Ortho-Biotech	NULL
)	NULL
or	NULL
anti-TCR	NULL
af	NULL
(	NULL
T	NULL
Cell	NULL
Diagnostics	NULL
,	NULL
Woburn	NULL
,	NULL
MA	NULL
)	NULL
antibodies	NULL
immobilized	NULL
on	NULL
polystyrene	NULL
surfaces	NULL
.	NULL

Antibodies	NULL
(	NULL
10	NULL
ug/ml	NULL
in	NULL
PBS	NULL
)	NULL
were	NULL
immobilized	NULL
by	NULL
incubating	NULL
in	NULL
polystyrene	NULL
tissue	NULL
culture	NULL
flasks	NULL
at	NULL
37°C	NULL
for	NULL
8-5	NULL
h.	NULL
PHA	NULL
,	NULL
phorbol	NULL
12-myristate	NULL
18-acetate	NULL
(	NULL
PMA	NULL
)	NULL
,	NULL
and	NULL
ionomycin	NULL
(	NULL
ION	NULL
)	NULL
were	NULL
from	NULL
Sigma	NULL
and	NULL
were	NULL
used	NULL
at	NULL
2.5	NULL
pg/ml	NULL
,	NULL
10	NULL
ng/ml	NULL
,	NULL
and	NULL
350	NULL
ng/ml	NULL
,	NULL
respectively	NULL
.	NULL

rIL-2	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
)	NULL
was	NULL
used	NULL
at	NULL
20-80	NULL
units/ml	NULL
.	NULL

Cyclosporin	NULL
A	NULL
(	NULL
CsA	NULL
)	NULL
and	NULL
rapamycin	NULL
(	NULL
RAP	NULL
)	NULL
(	NULL
Biomol	NULL
,	NULL
Plymouth	NULL
,	NULL
PA	NULL
)	NULL
were	NULL
used	NULL
at	NULL
2.5	NULL
and	NULL
1	NULL
pg/ml	NULL
,	NULL
respectively	NULL
.	NULL

Mimosine	NULL
(	NULL
Biomol	NULL
)	NULL
was	NULL
used	NULL
at	NULL
100	NULL
and	NULL
25	NULL
ug/ml	NULL
for	NULL
24-	NULL
and	NULL
72-h	NULL
cultures	NULL
,	NULL
respectively	NULL
.	NULL

Actinomycin	NULL
D	NULL
(	NULL
Act	NULL
D	NULL
)	NULL
and	NULL
cycloheximide	NULL
(	NULL
CHX	NULL
)	NULL
were	NULL
from	NULL
Sigma	NULL
and	NULL
were	NULL
used	NULL
at	NULL
2.5	NULL
and	NULL
10	NULL
ug/ml	NULL
,	NULL
respectively	NULL
.	NULL

Activation	NULL
Assay-After	NULL
65	NULL
h	NULL
of	NULL
incubation	NULL
with	NULL
different	NULL
agents	NULL
,	NULL
cells	NULL
were	NULL
treated	NULL
in	NULL
duplicate	NULL
with	NULL
1	NULL
mCi	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
thymidine/ml	NULL
and	NULL
incubated	NULL
for	NULL
an	NULL
additional	NULL
4-6	NULL
h	NULL
;	NULL
the	NULL
incorporation	NULL
of	NULL
was	NULL
determined	NULL
by	NULL
liquid	NULL
scintillation	NULL
counting	NULL
.	NULL

Differential	NULL
Display	NULL
Reverse	NULL
Transcription	NULL
PCR-DD-RT-PCR	NULL
was	NULL
done	NULL
in	NULL
duplicate	NULL
with	NULL
300	NULL
and	NULL
600	NULL
ng	NULL
of	NULL
total	NULL
RNA	NULL
from	NULL
untreated	NULL
and	NULL
OKT3-treated	NULL
PBMCs	NULL
using	NULL
instructions	NULL
and	NULL
primers	NULL
from	NULL
a	NULL
Differential	NULL
Display	NULL
Kit	NULL
purchased	NULL
from	NULL
Display	NULL
Systems	NULL
(	NULL
Los	NULL
Angeles	NULL
)	NULL
.	NULL

Isolation	NULL
of	NULL
5	NULL
and	NULL
3	NULL
'	NULL
RNA	NULL
Sequences-The	NULL
5	NULL
'	NULL
and	NULL
3	NULL
'	NULL
ends	NULL
of	NULL
mRNA	NULL
were	NULL
isolated	NULL
by	NULL
using	NULL
the	NULL
rapid	NULL
amplification	NULL
of	NULL
cDNA	NULL
ends	NULL
(	NULL
RACE	NULL
)	NULL
procedure	NULL
(	NULL
23	NULL
)	NULL
and	NULL
a	NULL
PromoterFinder	NULL
DNA	NULL
walking	NULL
kit	NULL
(	NULL
CLONTECH	NULL
)	NULL
.	NULL

PCR	NULL
products	NULL
were	NULL
cloned	NULL
and	NULL
sequenced	NULL
using	NULL
the	NULL
ABI	NULL
automatic	NULL
DNA	NULL
sequencer	NULL
(	NULL
model	NULL
377	NULL
)	NULL
.	NULL

The	NULL
most	NULL
updated	NULL
nucleic	NULL
acid	NULL
data	NULL
banks	NULL
(	NULL
GenBank	NULL
and	NULL
Entrez	NULL
)	NULL
were	NULL
searched	NULL
using	NULL
GCG	NULL
software	NULL
(	NULL
University	NULL
of	NULL
Wisconsin	NULL
)	NULL
.	NULL

RNase	NULL
Protection	NULL
Assay-RNase	NULL
protection	NULL
assay	NULL
was	NULL
performed	NULL
using	NULL
RiboQuant	NULL
Multi-Probe	NULL
RNase	NULL
protection	NULL
system	NULL
kit	NULL
purchased	NULL
from	NULL
Pharmingen	NULL
(	NULL
San	NULL
Diego	NULL
)	NULL
.	NULL

The	NULL
RXRa	NULL
probe	NULL
was	NULL
generated	NULL
from	NULL
pNotA/T7	NULL
plasmid	NULL
(	NULL
5	NULL
Prime	NULL
-	NULL
>	NULL
3	NULL
Prime	NULL
)	NULL
in	NULL
which	NULL
a	NULL
802-base	NULL
pair	NULL
PCR	NULL
fragment	NULL
of	NULL
RXRa	NULL
cDNA	NULL
was	NULL
cloned	NULL
(	NULL
the	NULL
cDNA	NULL
fragment	NULL
was	NULL
generated	NULL
by	NULL
RT-PCR	NULL
using	NULL
primers	NULL
from	NULL
the	NULL
newly	NULL
isolated	NULL
sequence	NULL
;	NULL
see	NULL
below	NULL
)	NULL
.	NULL

Control	NULL
plasmids	NULL
containing	NULL
GAPDH	NULL
and	NULL
L832	NULL
cDNA	NULL
sequences	NULL
were	NULL
purchased	NULL
from	NULL
Pharmingen	NULL
.	NULL

All	NULL
three	NULL
plasmids	NULL
were	NULL
transcribed	NULL
in	NULL
a	NULL
single	NULL
tube	NULL
using	NULL
T7	NULL
RNA	NULL
polymerase	NULL
according	NULL
to	NULL
the	NULL
instructions	NULL
in	NULL
the	NULL
kit	NULL
.	NULL

RNase	NULL
protection	NULL
was	NULL
performed	NULL
using	NULL
total	NULL
RNA	NULL
,	NULL
and	NULL
the	NULL
products	NULL
were	NULL
resolved	NULL
in	NULL
8	NULL
M	NULL
urea	NULL
,	NULL
6	NULL
%	NULL
polyacrylamide	NULL
gels	NULL
.	NULL

The	NULL
gels	NULL
were	NULL
dried	NULL
and	NULL
scanned	NULL
using	NULL
a	NULL
bio-imaging	NULL
analyzer	NULL
(	NULL
Bas	NULL
1000	NULL
,	NULL
Fuji	NULL
)	NULL
and	NULL
also	NULL
exposed	NULL
to	NULL
x-ray	NULL
films	NULL
.	NULL

RT-PCR-The	NULL
equal	NULL
amount	NULL
of	NULL
RNA	NULL
used	NULL
for	NULL
RT-PCR	NULL
was	NULL
determined	NULL
from	NULL
absorbance	NULL
at	NULL
260	NULL
nm	NULL
(	NULL
A	NULL
,	NULL
,	NULL
,	NULL
)	NULL
,	NULL
the	NULL
intensity	NULL
of	NULL
the	NULL
total	NULL
RNA	NULL
bands	NULL
on	NULL
an	NULL
agarose	NULL
gel	NULL
,	NULL
and	NULL
bands	NULL
obtained	NULL
after	NULL
RT-PCR	NULL
of	NULL
18	NULL
S	NULL
ribosomal	NULL
RNA	NULL
,	NULL
the	NULL
expression	NULL
of	NULL
which	NULL
was	NULL
not	NULL
affected	NULL
by	NULL
any	NULL
of	NULL
the	NULL
treatments	NULL
in	NULL
this	NULL
study	NULL
.	NULL

The	NULL
analysis	NULL
of	NULL
the	NULL
PCR	NULL
products	NULL
was	NULL
done	NULL
when	NULL
the	NULL
reactions	NULL
were	NULL
in	NULL
the	NULL
linear	NULL
range	NULL
and	NULL
the	NULL
amount	NULL
of	NULL
product	NULL
was	NULL
directly	NULL
proportional	NULL
to	NULL
the	NULL
amount	NULL
of	NULL
input	NULL
cDNA	NULL
.	NULL

This	NULL
was	NULL
accomplished	NULL
by	NULL
quantitating	NULL
the	NULL
product	NULL
accumulation	NULL
at	NULL
different	NULL
cycle	NULL
numbers	NULL
.	NULL

Under	NULL
the	NULL
conditions	NULL
described	NULL
,	NULL
750-24,000	NULL
copies	NULL
of	NULL
RXRa	NULL
DNA	NULL
could	NULL
be	NULL
amplified	NULL
in	NULL
the	NULL
linear	NULL
range	NULL
.	NULL

Half	NULL
a	NULL
microgram	NULL
of	NULL
total	NULL
RNA	NULL
was	NULL
reverse	NULL
transcribed	NULL
in	NULL
duplicate	NULL
with	NULL
200	NULL
units	NULL
of	NULL
Superscript	NULL
II	NULL
RNase	NULL
H	NULL
reverse	NULL
transcriptase	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Inc.	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
2.5	NULL
uM	NULL
random	NULL
hexamers	NULL
.	NULL

PCR	NULL
was	NULL
performed	NULL
for	NULL
25	NULL
cycles	NULL
at	NULL
94	NULL
°C	NULL
for	NULL
30	NULL
s	NULL
,	NULL
58	NULL
°C	NULL
for	NULL
30	NULL
s	NULL
,	NULL
and	NULL
68	NULL
°C	NULL
for	NULL
1	NULL
min	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
[	NULL
a-*P	NULL
]	NULL
dCTP	NULL
,	NULL
and	NULL
the	NULL
products	NULL
were	NULL
electrophoresed	NULL
in	NULL
6	NULL
%	NULL
precast	NULL
polyacrylamide	NULL
gels	NULL
(	NULL
Novex	NULL
,	NULL
San	NULL
Diego	NULL
)	NULL
.	NULL

The	NULL
gels	NULL
were	NULL
dried	NULL
and	NULL
scanned	NULL
for	NULL
quantitation	NULL
of	NULL
the	NULL
PCR	NULL
products	NULL
using	NULL
a	NULL
bio-imaging	NULL
analyzer	NULL
(	NULL
Bas	NULL
1000	NULL
,	NULL
Fuji	NULL
)	NULL
.	NULL

Primer	NULL
pairs	NULL
used	NULL
for	NULL
RXRa	NULL
PCR	NULL
were	NULL
5'-AGGGCTGGGACTGTTTCG	NULL
(	NULL
5000-5017	NULL
)	NULL
,	NULL
5-CCACGATGTTTCA-GAGACAATCGTACG	NULL
(	NULL
5301-5275	NULL
)	NULL
from	NULL
the	NULL
newly	NULL
isolated	NULL
sequence	NULL
,	NULL
and	NULL
5'-CCATAAGGAAGGTGTCAATGG	NULL
(	NULL
1412-1432	NULL
)	NULL
,	NULL
5-AGAAGGTC-TATGCGTCCTTGG	NULL
(	NULL
1276	NULL
-1256	NULL
)	NULL
from	NULL
the	NULL
published	NULL
sequence	NULL
(	NULL
24	NULL
)	NULL
.	NULL

The	NULL
primer	NULL
pair	NULL
for	NULL
18	NULL
S	NULL
rRNA	NULL
was	NULL
5-CGAAGACGATCAGATACCGTCG-TAG	NULL
(	NULL
1047-1071	NULL
)	NULL
and	NULL
5'-GGGCATCACAGACCTGTTATTGCTC	NULL
(	NULL
1503-1479	NULL
)	NULL
(	NULL
25	NULL
)	NULL
.	NULL

Primers	NULL
for	NULL
IL2	NULL
receptor	NULL
were	NULL
5'-ATCAGCGTCCTCCTCCT-GAGT	NULL
(	NULL
981-951	NULL
)	NULL
and	NULL
5'-CAAGCACAACGGATGTCTCC	NULL
(	NULL
1116-1097	NULL
)	NULL
(	NULL
26	NULL
)	NULL
.	NULL

Western	NULL
Blot-100	NULL
pug	NULL
of	NULL
protein	NULL
were	NULL
electrophoresed	NULL
in	NULL
a	NULL
10	NULL
%	NULL
21211	NULL
NuPAGE	NULL
Bis	NULL
Tris	NULL
gel	NULL
using	NULL
NuPAGE	NULL
MOPS-SDS	NULL
running	NULL
buffer	NULL
(	NULL
Novex	NULL
)	NULL
and	NULL
transferred	NULL
to	NULL
polyvinyldifluoride	NULL
membrane	NULL
using	NULL
XCell	NULL
blot	NULL
module	NULL
(	NULL
Novex	NULL
)	NULL
.	NULL

The	NULL
membrane	NULL
was	NULL
blocked	NULL
with	NULL
Blocker	NULL
Blotto	NULL
(	NULL
Pierce	NULL
)	NULL
and	NULL
treated	NULL
overnight	NULL
at	NULL
4°C	NULL
with	NULL
1:1000	NULL
dilution	NULL
of	NULL
RXRa	NULL
(	NULL
D-20	NULL
)	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
,	NULL
a	NULL
rabbit	NULL
polyclonal	NULL
antibody	NULL
against	NULL
a	NULL
peptide	NULL
corresponding	NULL
to	NULL
amino	NULL
acids	NULL
2-21	NULL
of	NULL
human	NULL
RXRa	NULL
,	NULL
or	NULL
1:2000	NULL
dilution	NULL
of	NULL
a	NULL
monoclonal	NULL
anti-a-tubulin	NULL
antibody	NULL
(	NULL
Sigma	NULL
)	NULL
.	NULL

Proteins	NULL
were	NULL
detected	NULL
using	NULL
the	NULL
ECL	NULL
Western	NULL
blotting	NULL
detection	NULL
system	NULL
from	NULL
Amer-sham	NULL
Pharmacia	NULL
Biotech	NULL
.	NULL

Electrophoretic	NULL
Mobility	NULL
Shift	NULL
Assay	NULL
(	NULL
EMSA	NULL
)	NULL
-The	NULL
DNA	NULL
binding	NULL
activity	NULL
of	NULL
RXRs	NULL
was	NULL
studied	NULL
by	NULL
EMSA	NULL
using	NULL
oligonucleotides	NULL
corresponding	NULL
to	NULL
CRBPII	NULL
RXRE	NULL
(	NULL
AGCTTCAGGTCAGAGGTCAGAGAGCT	NULL
)	NULL
.	NULL

AP-1	NULL
binding	NULL
activity	NULL
was	NULL
determined	NULL
using	NULL
the	NULL
triplet	NULL
AP-1	NULL
consensus	NULL
sequence	NULL
TGACTCATGACTCATGACTCA	NULL
and	NULL
the	NULL
AP-1	NULL
mutant	NULL
sequence	NULL
CGACTCGCGACTCGCGACTCG	NULL
.	NULL

Spl	NULL
binding	NULL
activity	NULL
was	NULL
determined	NULL
using	NULL
the	NULL
sequence	NULL
ATTCGATCGGGGCGGGGCGAGC	NULL
.	NULL

2-5	NULL
ug	NULL
of	NULL
nuclear	NULL
extracts	NULL
were	NULL
incubated	NULL
for	NULL
10	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
with	NULL
0.5	NULL
ug	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
in	NULL
10	NULL
mM	NULL
Tris	NULL
,	NULL
50	NULL
mM	NULL
NaCl	NULL
,	NULL
0.5	NULL
mm	NULL
DTT	NULL
,	NULL
0.5	NULL
mm	NULL
EDTA	NULL
,	NULL
L	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
and	NULL
4	NULL
%	NULL
glycerol	NULL
in	NULL
a	NULL
total	NULL
volume	NULL
of	NULL
10	NULL
pl	NULL
followed	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
1	NULL
ng	NULL
of	NULL
°°P	NULL
end-labeled	NULL
probe	NULL
for	NULL
20	NULL
min	NULL
at	NULL
room	NULL
tempera-ture	NULL
.	NULL

For	NULL
the	NULL
competition	NULL
experiment	NULL
,	NULL
a	NULL
50-fold	NULL
excess	NULL
of	NULL
unlabeled	NULL
probe	NULL
was	NULL
added	NULL
before	NULL
the	NULL
addition	NULL
of	NULL
the	NULL
*°P	NULL
end-labeled	NULL
probe	NULL
.	NULL

The	NULL
protein-DNA	NULL
complexes	NULL
were	NULL
resolved	NULL
in	NULL
a	NULL
6	NULL
%	NULL
DNA	NULL
retardation	NULL
gel	NULL
(	NULL
Novex	NULL
)	NULL
.	NULL

The	NULL
gels	NULL
were	NULL
dried	NULL
and	NULL
scanned	NULL
for	NULL
quantitation	NULL
using	NULL
a	NULL
bio-imaging	NULL
analyzer	NULL
(	NULL
Bas	NULL
1000	NULL
,	NULL
Fuji	NULL
)	NULL
and	NULL
also	NULL
exposed	NULL
to	NULL
x-ray	NULL
films	NULL
.	NULL

Nuclear	NULL
Run-on	NULL
Transcription	NULL
Assay-10°	NULL
cells	NULL
were	NULL
washed	NULL
in	NULL
PBS	NULL
,	NULL
resuspended	NULL
in	NULL
1	NULL
ml	NULL
of	NULL
lysis	NULL
buffer	NULL
(	NULL
10	NULL
mM	NULL
Tris	NULL
,	NULL
pH	NULL
7.4	NULL
,	NULL
3	NULL
mM	NULL
CaCl	NULL
,	NULL
,	NULL
2	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
1	NULL
%	NULL
Nonidet	NULL
P-40	NULL
)	NULL
and	NULL
homogenized	NULL
in	NULL
a	NULL
Dounce	NULL
homoge-nizer	NULL
.	NULL

Nuclei	NULL
were	NULL
pelleted	NULL
,	NULL
washed	NULL
once	NULL
,	NULL
and	NULL
stored	NULL
in	NULL
200	NULL
ul	NULL
of	NULL
10	NULL
mM	NULL
Tris	NULL
,	NULL
pH	NULL
8.3	NULL
,	NULL
40	NULL
%	NULL
glycerol	NULL
,	NULL
5	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
1	NULL
mm	NULL
EDTA	NULL
at	NULL
-180	NULL
°C	NULL
.	NULL

Transcription	NULL
was	NULL
performed	NULL
for	NULL
45	NULL
min	NULL
at	NULL
30	NULL
°C	NULL
with	NULL
200	NULL
pl	NULL
of	NULL
nuclei	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
5	NULL
mM	NULL
Tris	NULL
,	NULL
pH	NULL
8.0	NULL
,	NULL
2.5	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
150	NULL
mM	NULL
KCl	NULL
,	NULL
0.25	NULL
mM	NULL
each	NULL
of	NULL
ATP	NULL
,	NULL
GTP	NULL
,	NULL
UTP	NULL
,	NULL
and	NULL
200	NULL
wCi	NULL
of	NULL
[	NULL
a-	NULL
``	NULL
``	NULL
P	NULL
]	NULL
CTP	NULL
(	NULL
8,000	NULL
Ci/mmol	NULL
)	NULL
.	NULL

The	NULL
mixture	NULL
was	NULL
treated	NULL
with	NULL
150	NULL
units	NULL
of	NULL
RQ1	NULL
DNase	NULL
(	NULL
Promega	NULL
)	NULL
and	NULL
incubated	NULL
for	NULL
another	NULL
15	NULL
min	NULL
followed	NULL
by	NULL
treatment	NULL
with	NULL
10	NULL
mg/ml	NULL
proteinase	NULL
K	NULL
at	NULL
37	NULL
°C	NULL
for	NULL
45	NULL
min	NULL
.	NULL

RNA	NULL
was	NULL
isolated	NULL
using	NULL
Trizol	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Inc.	NULL
)	NULL
and	NULL
heated	NULL
for	NULL
10	NULL
min	NULL
at	NULL
95	NULL
°C	NULL
before	NULL
hybridization	NULL
.	NULL

Equivalent	NULL
amounts	NULL
of	NULL
radioactivity	NULL
were	NULL
hybridized	NULL
to	NULL
nylon	NULL
membranes	NULL
on	NULL
which	NULL
10	NULL
pg	NULL
of	NULL
various	NULL
linearized	NULL
and	NULL
denatured	NULL
plasmids	NULL
were	NULL
slot	NULL
blotted	NULL
.	NULL

Hybridizations	NULL
were	NULL
performed	NULL
for	NULL
3	NULL
days	NULL
at	NULL
42	NULL
°C	NULL
in	NULL
6	NULL
x	NULL
SSPE	NULL
,	NULL
1	NULL
X	NULL
Denhardt	NULL
,	NULL
0.5	NULL
%	NULL
SDS	NULL
,	NULL
50	NULL
%	NULL
formamide	NULL
,	NULL
50	NULL
ug/ml	NULL
salmon	NULL
sperm	NULL
DNA	NULL
and	NULL
washed	NULL
at	NULL
0.1	NULL
X	NULL
SSPE	NULL
,	NULL
0.1	NULL
%	NULL
SDS	NULL
at	NULL
56	NULL
°C	NULL
.	NULL

The	NULL
membranes	NULL
were	NULL
scanned	NULL
for	NULL
quantitation	NULL
using	NULL
a	NULL
bio-imaging	NULL
analyzer	NULL
(	NULL
Bas	NULL
1000	NULL
,	NULL
Fuji	NULL
)	NULL
and	NULL
also	NULL
exposed	NULL
to	NULL
x-ray	NULL
films	NULL
.	NULL

Cell	NULL
Cycle	NULL
Analysis-For	NULL
DNA	NULL
content	NULL
measurement	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
fixed	NULL
in	NULL
70	NULL
%	NULL
ethanol	NULL
on	NULL
ice	NULL
for	NULL
30	NULL
min	NULL
,	NULL
washed	NULL
with	NULL
PBS	NULL
,	NULL
and	NULL
incubated	NULL
with	NULL
200	NULL
units/ml	NULL
DNase-free	NULL
RNase	NULL
for	NULL
15	NULL
min	NULL
at	NULL
87°C	NULL
.	NULL

Cells	NULL
were	NULL
stained	NULL
with	NULL
50	NULL
ug/ml	NULL
propidium	NULL
iodide	NULL
and	NULL
analyzed	NULL
with	NULL
a	NULL
Coulter	NULL
flow	NULL
cytometer	NULL
using	NULL
an	NULL
argon	NULL
laser	NULL
.	NULL

Debris	NULL
and	NULL
doublets	NULL
were	NULL
excluded	NULL
by	NULL
electronic	NULL
gating	NULL
on	NULL
a	NULL
cytogram	NULL
drawn	NULL
from	NULL
the	NULL
peak	NULL
versus	NULL
linear	NULL
PI	NULL
signal	NULL
.	NULL

Histograms	NULL
of	NULL
DNA	NULL
content	NULL
of	NULL
the	NULL
gated	NULL
events	NULL
were	NULL
drawn	NULL
using	NULL
the	NULL
Multicycle	NULL
program	NULL
.	NULL

RESULTS	NULL
Cloning	NULL
and	NULL
Sequencing	NULL
of	NULL
Differentially	NULL
Expressed	NULL
Human	NULL
RXRa	NULL
mRNA	NULL
and	NULL
Isolation	NULL
of	NULL
3°	NULL
Sequences-Electrophoretic	NULL
analysis	NULL
of	NULL
OKT3-treated	NULL
and	NULL
untreated	NULL
DD-RT-PCR	NULL
products	NULL
revealed	NULL
a	NULL
complex	NULL
pattern	NULL
of	NULL
different	NULL
cDNAs	NULL
.	NULL

A	NULL
number	NULL
of	NULL
differentially	NULL
amplified	NULL
products	NULL
were	NULL
cloned	NULL
and	NULL
sequenced	NULL
.	NULL

One	NULL
of	NULL
them	NULL
(	NULL
designated	NULL
clone	NULL
5	NULL
)	NULL
,	NULL
which	NULL
was	NULL
down-regulated	NULL
in	NULL
OKT3-treated	NULL
PBMCs	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
and	NULL
was	NULL
not	NULL
related	NULL
to	NULL
any	NULL
known	NULL
sequence	NULL
in	NULL
the	NULL
GenBank	NULL
,	NULL
was	NULL
further	NULL
studied	NULL
.	NULL

Northern	NULL
blot	NULL
hybridization	NULL
using	NULL
the	NULL
clone	NULL
5	NULL
cDNA	NULL
probe	NULL
identified	NULL
this	NULL
RNA	NULL
as	NULL
an	NULL
approximately	NULL
5.4-kb	NULL
RNA	NULL
that	NULL
was	NULL
expressed	NULL
in	NULL
PBMCs	NULL
and	NULL
also	NULL
in	NULL
a	NULL
number	NULL
of	NULL
human	NULL
tissues	NULL
like	NULL
spleen	NULL
,	NULL
thymus	NULL
,	NULL
prostate	NULL
,	NULL
testis	NULL
,	NULL
ovary	NULL
,	NULL
small	NULL
intestine	NULL
,	NULL
and	NULL
colon	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Based	NULL
on	NULL
the	NULL
sequence	NULL
information	NULL
obtained	NULL
from	NULL
the	NULL
clone	NULL
5	NULL
,	NULL
3	NULL
'	NULL
and	NULL
5	NULL
'	NULL
ends	NULL
of	NULL
this	NULL
RNA	NULL
were	NULL
isolated	NULL
using	NULL
RACE	NULL
.	NULL

An	NULL
approximately	NULL
450-base	NULL
pair	NULL
sequence	NULL
(	NULL
excluding	NULL
the	NULL
poly	NULL
(	NULL
A	NULL
)	NULL
tail	NULL
)	NULL
was	NULL
identified	NULL
by	NULL
3	NULL
'	NULL
RACE	NULL
,	NULL
and	NULL
3.1	NULL
kb	NULL
of	NULL
cDNA	NULL
sequence	NULL
was	NULL
obtained	NULL
by	NULL
5	NULL
RACE	NULL
and	NULL
5	NULL
genomic	NULL
DNA	NULL
walking	NULL
,	NULL
followed	NULL
by	NULL
RT-PCR	NULL
using	NULL
primers	NULL
from	NULL
genomic	NULL
DNA	NULL
sequences	NULL
.	NULL

Comparison	NULL
of	NULL
these	NULL
sequences	NULL
revealed	NULL
that	NULL
about	NULL
200	NULL
nucle-	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
21212	NULL
1	NULL
2	NULL
_1	NULL
Fic	NULL
.	NULL

1	NULL
.	NULL

Differential	NULL
display	NULL
of	NULL
a	NULL
down-regulated	NULL
mRNA	NULL
.	NULL

Polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
of	NULL
DD-RT-PCR	NULL
products	NULL
showing	NULL
down-regulation	NULL
of	NULL
an	NULL
mRNA	NULL
(	NULL
marked	NULL
with	NULL
an	NULL
arrow	NULL
and	NULL
later	NULL
shown	NULL
to	NULL
be	NULL
RXRa	NULL
)	NULL
after	NULL
treatment	NULL
of	NULL
PBMCs	NULL
with	NULL
OKT3	NULL
for	NULL
72	NULL
h.	NULL
Lanes	NULL
1	NULL
and	NULL
2	NULL
are	NULL
RT-PCR	NULL
products	NULL
from	NULL
untreated	NULL
and	NULL
OKT3-treated	NULL
PBMCs	NULL
,	NULL
respectively	NULL
.	NULL

otides	NULL
from	NULL
the	NULL
5	NULL
end	NULL
of	NULL
this	NULL
newly	NULL
isolated	NULL
cDNA	NULL
were	NULL
identical	NULL
to	NULL
human	NULL
RXRa	NULL
(	NULL
24	NULL
)	NULL
.	NULL

RXRa	NULL
mRNA	NULL
has	NULL
been	NULL
characterized	NULL
as	NULL
a	NULL
5.4-kb	NULL
mRNA	NULL
,	NULL
but	NULL
only	NULL
about	NULL
1.8	NULL
kb	NULL
of	NULL
the	NULL
mRNA	NULL
sequence	NULL
has	NULL
been	NULL
reported	NULL
(	NULL
24	NULL
)	NULL
.	NULL

RT-PCR	NULL
using	NULL
primers	NULL
from	NULL
the	NULL
newly	NULL
isolated	NULL
sequences	NULL
and	NULL
the	NULL
published	NULL
regions	NULL
of	NULL
RXRa	NULL
yielded	NULL
the	NULL
expected	NULL
size	NULL
cDNA	NULL
PCR	NULL
products	NULL
,	NULL
and	NULL
sequence	NULL
analysis	NULL
of	NULL
these	NULL
PCR	NULL
products	NULL
established	NULL
that	NULL
the	NULL
newly	NULL
isolated	NULL
sequence	NULL
was	NULL
indeed	NULL
the	NULL
3	NULL
'	NULL
end	NULL
of	NULL
human	NULL
RXRa	NULL
mRNA	NULL
.	NULL

This	NULL
was	NULL
further	NULL
confirmed	NULL
by	NULL
Northern	NULL
blot	NULL
hybridization	NULL
using	NULL
an	NULL
RXRa	NULL
cDNA	NULL
probe	NULL
prepared	NULL
by	NULL
PCR	NULL
using	NULL
the	NULL
primers	NULL
from	NULL
the	NULL
published	NULL
RXRa	NULL
cDNA	NULL
sequences	NULL
.	NULL

This	NULL
probe	NULL
hybridized	NULL
to	NULL
the	NULL
same	NULL
5.4-kb	NULL
RNA	NULL
as	NULL
did	NULL
the	NULL
probe	NULL
from	NULL
the	NULL
newly	NULL
isolated	NULL
sequence	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Sequence	NULL
analysis	NULL
of	NULL
the	NULL
newly	NULL
isolated	NULL
RNA	NULL
(	NULL
approximately	NULL
3.6	NULL
kb	NULL
)	NULL
showed	NULL
two	NULL
additional	NULL
open	NULL
reading	NULL
frames	NULL
designated	NULL
ORF-2	NULL
(	NULL
2125-2877	NULL
)	NULL
and	NULL
ORF-3	NULL
(	NULL
4260-4754	NULL
)	NULL
,	NULL
which	NULL
can	NULL
code	NULL
for	NULL
polypeptides	NULL
of	NULL
251	NULL
and	NULL
165	NULL
amino	NULL
acids	NULL
,	NULL
respectively	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

CD3	NULL
Cross-linking	NULL
Induces	NULL
Down-regulation	NULL
of	NULL
RXRa	NULL
Expression	NULL
in	NULL
PBMCs-Treatment	NULL
of	NULL
PBMCs	NULL
with	NULL
anti-CD3	NULL
antibodies	NULL
resulted	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
T	NULL
cells	NULL
as	NULL
shown	NULL
by	NULL
[	NULL
H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
.	NULL

RNase	NULL
protection	NULL
assay	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
and	NULL
RT-PCR	NULL
(	NULL
using	NULL
primers	NULL
from	NULL
the	NULL
newly	NULL
isolated	NULL
sequence	NULL
and	NULL
from	NULL
the	NULL
published	NULL
RXRa	NULL
sequence	NULL
)	NULL
were	NULL
used	NULL
to	NULL
estimate	NULL
the	NULL
relative	NULL
levels	NULL
of	NULL
RXRa	NULL
mRNA	NULL
.	NULL

There	NULL
was	NULL
an	NULL
approximately	NULL
90	NULL
%	NULL
decrease	NULL
in	NULL
the	NULL
levels	NULL
of	NULL
RXRa	NULL
mRNA	NULL
when	NULL
PBMCs	NULL
were	NULL
treated	NULL
with	NULL
OKT3	NULL
for	NULL
72	NULL
h.	NULL
Fig	NULL
.	NULL

2B	NULL
shows	NULL
the	NULL
kinetics	NULL
of	NULL
this	NULL
down-regulation	NULL
.	NULL

The	NULL
data	NULL
show	NULL
that	NULL
there	NULL
was	NULL
a	NULL
70	NULL
%	NULL
decrease	NULL
in	NULL
the	NULL
RXRa	NULL
mRNA	NULL
levels	NULL
in	NULL
first	NULL
24	NULL
h	NULL
and	NULL
,	NULL
after	NULL
72	NULL
h	NULL
of	NULL
OKT3	NULL
treatment	NULL
,	NULL
a	NULL
90-95	NULL
%	NULL
reduction	NULL
in	NULL
the	NULL
level	NULL
of	NULL
the	NULL
RXRa	NULL
mRNA	NULL
.	NULL

For	NULL
comparison	NULL
,	NULL
cDNA	NULL
samples	NULL
were	NULL
also	NULL
amplified	NULL
with	NULL
IL2-receptor	NULL
specific	NULL
primers	NULL
that	NULL
served	NULL
as	NULL
an	NULL
activation	NULL
marker	NULL
.	NULL

To	NULL
demonstrate	NULL
that	NULL
the	NULL
down-regulation	NULL
of	NULL
RXRa	NULL
mRNA	NULL
was	NULL
T	NULL
cell-specific	NULL
,	NULL
purified	NULL
CD4*/CD8*	NULL
T	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
OKT3	NULL
or	NULL
the	NULL
combination	NULL
of	NULL
PMA	NULL
+	NULL
ION	NULL
,	NULL
known	NULL
to	NULL
induce	NULL
T	NULL
cell	NULL
activation	NULL
(	NULL
10	NULL
)	NULL
.	NULL

The	NULL
levels	NULL
of	NULL
RXRa	NULL
mRNA	NULL
were	NULL
reduced	NULL
in	NULL
the	NULL
purified	NULL
T	NULL
cells	NULL
after	NULL
both	NULL
treatments	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
revealed	NULL
that	NULL
the	NULL
OKT3-induced	NULL
down-regulation	NULL
of	NULL
RXRa	NULL
was	NULL
also	NULL
observed	NULL
at	NULL
the	NULL
protein	NULL
level	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Down-regulation	NULL
of	NULL
RXRa	NULL
mRNA	NULL
Expression	NULL
in	NULL
PBMCs	NULL
by	NULL
Other	NULL
T	NULL
Cell-activating	NULL
Agents-To	NULL
investigate	NULL
whether	NULL
the	NULL
decrease	NULL
in	NULL
the	NULL
RXRa	NULL
mRNA	NULL
expression	NULL
,	NULL
seen	NULL
after	NULL
CD3	NULL
cross-linking	NULL
of	NULL
PBMCs	NULL
,	NULL
could	NULL
also	NULL
be	NULL
achieved	NULL
by	NULL
stimulating	NULL
cells	NULL
with	NULL
other	NULL
known	NULL
T	NULL
cell-proliferating	NULL
agents	NULL
,	NULL
we	NULL
treated	NULL
PBMCs	NULL
with	NULL
immobilized	NULL
monoclonal	NULL
anti-TCR	NULL
«	NULL
f	NULL
antibody	NULL
,	NULL
PMA	NULL
Activation-induced	NULL
RXRa	NULL
Down-regulation	NULL
in	NULL
T	NULL
Lymphocytes	NULL
A	NULL
Probe	NULL
OKT3	NULL
Treated	NULL
Untreated	NULL
we	NULL
_	NULL
<	NULL
-	NULL
302	NULL
(	NULL
RXRo	NULL
)	NULL
'	NULL
<	NULL
-	NULL
113	NULL
(	NULL
L32	NULL
)	NULL
<	NULL
-	NULL
96	NULL
(	NULL
GAPDH	NULL
)	NULL
&	NULL
<	NULL
-	NULL
L32	NULL
<	NULL
-	NULL
GAPDH	NULL
B	NULL
1	NULL
2	NULL
3	NULL
4	NULL
506	NULL
7	NULL
8	NULL
RXRe	NULL
@	NULL
*	NULL
-	NULL
@	NULL
IL-2R	NULL
“	NULL
-	NULL
©	NULL
-	NULL
e	NULL
rRNA	NULL
@	NULL
@	NULL
@	NULL
OC	NULL
@	NULL
%	NULL
eee	NULL
Fic	NULL
.	NULL

2	NULL
.	NULL

RNase	NULL
protection	NULL
analysis	NULL
and	NULL
kinetics	NULL
of	NULL
OKT3-induced	NULL
down-regulation	NULL
of	NULL
RXRa	NULL
«	NULL
mRNA	NULL
in	NULL
PBMCs	NULL
.	NULL

A	NULL
,	NULL
total	NULL
RNAs	NULL
from	NULL
untreated	NULL
and	NULL
OKT3-treated	NULL
PBMCs	NULL
were	NULL
subject	NULL
to	NULL
RNase	NULL
protection	NULL
analysis	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
.	NULL
``	NULL

GAPDH	NULL
and	NULL
L82	NULL
were	NULL
used	NULL
as	NULL
internal	NULL
controls	NULL
for	NULL
normalizing	NULL
the	NULL
total	NULL
RNA	NULL
concentrations	NULL
.	NULL

The	NULL
arrows	NULL
on	NULL
right	NULL
indicate	NULL
the	NULL
size	NULL
of	NULL
the	NULL
protected	NULL
fragments	NULL
.	NULL

For	NULL
clarity	NULL
,	NULL
a	NULL
shorter	NULL
x-ray	NULL
exposure	NULL
time	NULL
is	NULL
shown	NULL
for	NULL
GAPDH	NULL
and	NULL
L82	NULL
at	NULL
the	NULL
bottom	NULL
of	NULL
the	NULL
figure	NULL
.	NULL

B	NULL
,	NULL
PBMCs	NULL
were	NULL
treated	NULL
with	NULL
OKT3	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
,	NULL
``	NULL
and	NULL
cells	NULL
were	NULL
harvested	NULL
after	NULL
various	NULL
time	NULL
intervals	NULL
.	NULL

RXRa	NULL
,	NULL
IL2-	NULL
receptor	NULL
,	NULL
and	NULL
18	NULL
S	NULL
ribosomal	NULL
RNAs	NULL
were	NULL
amplified	NULL
from	NULL
total	NULL
RNA	NULL
by	NULL
RT-PCR	NULL
.	NULL

Lanes	NULL
1	NULL
,	NULL
3	NULL
,	NULL
5	NULL
,	NULL
and	NULL
7	NULL
are	NULL
,	NULL
respectively,12	NULL
,	NULL
24	NULL
,	NULL
48	NULL
,	NULL
and	NULL
72	NULL
h	NULL
untreated	NULL
PBMCs	NULL
.	NULL

Lanes	NULL
2	NULL
,	NULL
4	NULL
,	NULL
6	NULL
,	NULL
and	NULL
8	NULL
are	NULL
,	NULL
respectively	NULL
,	NULL
12	NULL
,	NULL
24	NULL
,	NULL
48	NULL
,	NULL
and	NULL
72	NULL
h	NULL
OKT3-treated	NULL
PBMCs	NULL
.	NULL

97	NULL
Kd	NULL
66	NULL
Kd	NULL
-	NULL
am	NULL
46	NULL
Kd	NULL
97	NULL
Kd	NULL
66	NULL
Kd	NULL
46	NULL
Ka-	NULL
--	NULL
~*~	NULL
®	NULL
*~	NULL
-o-Tubulin	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

Expression	NULL
of	NULL
RXRa	NULL
protein	NULL
in	NULL
PBMCs	NULL
after	NULL
OKT3	NULL
activation	NULL
.	NULL

PBMCs	NULL
(	NULL
10°/ml	NULL
)	NULL
were	NULL
treated	NULL
with	NULL
OKT3	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
CsA	NULL
.	NULL

After	NULL
72	NULL
h	NULL
,	NULL
cells	NULL
were	NULL
harvested	NULL
,	NULL
lysates	NULL
were	NULL
made	NULL
,	NULL
and	NULL
100	NULL
ug	NULL
of	NULL
protein	NULL
were	NULL
subjected	NULL
to	NULL
SDS-PAGE	NULL
.	NULL

After	NULL
transfer	NULL
to	NULL
a	NULL
membrane	NULL
,	NULL
RXRa	NULL
«	NULL
protein	NULL
was	NULL
detected	NULL
by	NULL
RXRa	NULL
(	NULL
D-20	NULL
)	NULL
antibody	NULL
using	NULL
ECL	NULL
Western	NULL
blotting	NULL
detection	NULL
system	NULL
from	NULL
Amersham	NULL
.	NULL

Lanes	NULL
1-3	NULL
are	NULL
,	NULL
respectively	NULL
,	NULL
untreated	NULL
,	NULL
OKT3	NULL
treated-	NULL
,	NULL
and	NULL
OKT3	NULL
+	NULL
CsA-treated	NULL
ly-sates	NULL
.	NULL

In	NULL
lane	NULL
4	NULL
,	NULL
12.5	NULL
pg	NULL
of	NULL
Helia	NULL
cell	NULL
nuclear	NULL
extract-phorbol	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
were	NULL
loaded	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
for	NULL
the	NULL
detection	NULL
of	NULL
RXRa	NULL
protein	NULL
.	NULL

The	NULL
membrane	NULL
was	NULL
also	NULL
blotted	NULL
with	NULL
an	NULL
anti-o-tubulin	NULL
antibody	NULL
to	NULL
demonstrate	NULL
that	NULL
equal	NULL
amount	NULL
of	NULL
protein	NULL
was	NULL
loaded	NULL
in	NULL
each	NULL
lane	NULL
.	NULL

+IO0N	NULL
,	NULL
PHA	NULL
,	NULL
concanavalin	NULL
A	NULL
,	NULL
IL2	NULL
,	NULL
or	NULL
PHA	NULL
+	NULL
IL2	NULL
(	NULL
Fig	NULL
.	NULL

44	NULL
)	NULL
.	NULL

RT-PCR	NULL
data	NULL
show	NULL
that	NULL
all	NULL
of	NULL
these	NULL
treatments	NULL
resulted	NULL
in	NULL
a	NULL
decrease	NULL
in	NULL
RXRa	NULL
mRNA	NULL
levels	NULL
when	NULL
compared	NULL
with	NULL
untreated	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

The	NULL
extent	NULL
of	NULL
RXRa	NULL
mRNA	NULL
down-regulation	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
Activation-induced	NULL
RXRa	NULL
Down-regulation	NULL
in	NULL
T	NULL
Lymphocytes	NULL
A	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
25000	NULL
20000	NULL
15000	NULL
pS	NULL
o.	NULL
o	NULL
10000	NULL
5000	NULL
O_gnﬂﬁn	NULL
%	NULL
ﬂﬁ-4244ﬁﬁd	NULL
t	NULL
id	NULL
=	NULL
=	NULL
G	NULL
s	NULL
°f	NULL
f	NULL
'if	NULL
;	NULL
f	NULL
i=	NULL
]	NULL
&	NULL
%	NULL
el	NULL
o	NULL
o	NULL
a	NULL
G	NULL
=	NULL
a	NULL
.	NULL

B	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10111213	NULL
I	NULL
RX	NULL
Ro	NULL
.	NULL

-	NULL
#	NULL
#	NULL
#	NULL
«	NULL
#	NULL
.	NULL

--	NULL
l	NULL
#	NULL
«	NULL
|	NULL
OI	NULL
rNA	NULL
C200	NULL
}	NULL
180	NULL
|-160	NULL
|-140	NULL
|-5	NULL
120	NULL
}	NULL
$	NULL
§	NULL
100	NULL
d	NULL
€	NULL
so	NULL
8	NULL
0	NULL
&	NULL
-	NULL
60	NULL
40	NULL
20	NULL
0	NULL
§	NULL
B	NULL
f	NULL
f	NULL
f	NULL
i	NULL
1	NULL
'	NULL
f	NULL
°	NULL
&	NULL
€	NULL
po	NULL
p	NULL
so	NULL
g	NULL
§	NULL
T	NULL
3	NULL
z	NULL
¢	NULL
fra	NULL
&	NULL
.	NULL

.	NULL

6	NULL
-	NULL
o	NULL
o	NULL
3	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

Effect	NULL
of	NULL
various	NULL
T	NULL
cell-proliferating	NULL
agents	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
RXRa	NULL
RNA	NULL
in	NULL
PBMCs	NULL
.	NULL

A	NULL
,	NULL
purified	NULL
PBMCs	NULL
(	NULL
10¢/ml	NULL
)	NULL
were	NULL
treated	NULL
with	NULL
various	NULL
reagents	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
.	NULL
``	NULL

After	NULL
65	NULL
h	NULL
of	NULL
culture	NULL
,	NULL
cells	NULL
were	NULL
treated	NULL
in	NULL
duplicate	NULL
with	NULL
1	NULL
uCi	NULL
of	NULL
|®H	NULL
]	NULL
thymidine/ml	NULL
and	NULL
incubated	NULL
for	NULL
an	NULL
additional	NULL
4-6	NULL
h.	NULL
The	NULL
cells	NULL
were	NULL
harvested	NULL
,	NULL
and	NULL
the	NULL
incorporation	NULL
of	NULL
was	NULL
determined	NULL
by	NULL
liquid	NULL
scintillation	NULL
counting	NULL
.	NULL

B	NULL
,	NULL
polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
of	NULL
RT-PCR	NULL
products	NULL
of	NULL
RNAs	NULL
isolated	NULL
from	NULL
PBMCs	NULL
after	NULL
various	NULL
treatments	NULL
.	NULL

Lanes	NULL
1-13	NULL
are	NULL
,	NULL
respectively	NULL
,	NULL
zero	NULL
time	NULL
,	NULL
untreated	NULL
,	NULL
OKT3	NULL
,	NULL
OKT3	NULL
+	NULL
CsA	NULL
,	NULL
OKT3	NULL
+	NULL
RAP	NULL
,	NULL
anti-TCR	NULL
af	NULL
,	NULL
anti-TCR	NULL
aB	NULL
+	NULL
CsA	NULL
,	NULL
PMA	NULL
+	NULL
ION	NULL
,	NULL
PMA	NULL
+	NULL
ION	NULL
+	NULL
CsA	NULL
,	NULL
PHA	NULL
,	NULL
PHA	NULL
+	NULL
IL2	NULL
,	NULL
IL2	NULL
,	NULL
and	NULL
concanavalin	NULL
A	NULL
.	NULL

C	NULL
,	NULL
quantitation	NULL
of	NULL
RXRa	NULL
RT-PCR	NULL
products	NULL
.	NULL

The	NULL
values	NULL
represent	NULL
the	NULL
mean	NULL
of	NULL
3-10	NULL
independent	NULL
experiments	NULL
with	NULL
standard	NULL
error	NULL
calculated	NULL
for	NULL
each	NULL
value	NULL
.	NULL

Fic	NULL
.	NULL

5	NULL
.	NULL

EMSA	NULL
of	NULL
OKT3-treated	NULL
PBMCs	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
subjected	NULL
to	NULL
EMSA	NULL
using	NULL
CRBPII	NULL
,	NULL
AP-1	NULL
,	NULL
AP-1	NULL
mutant	NULL
(	NULL
AP-1M	NULL
)	NULL
,	NULL
and	NULL
Sp1	NULL
double-stranded	NULL
oligonucleotide	NULL
probes	NULL
.	NULL

A	NULL
,	NULL
CRBPII	NULL
probe	NULL
.	NULL

Lane	NULL
1	NULL
,	NULL
probe	NULL
alone	NULL
;	NULL
lane	NULL
2	NULL
,	NULL
untreated	NULL
extract	NULL
;	NULL
lane	NULL
3	NULL
,	NULL
OKTS-treated	NULL
extract	NULL
;	NULL
lanes	NULL
4	NULL
and	NULL
5	NULL
are	NULL
untreated	NULL
and	NULL
OKT3-treated	NULL
extracts	NULL
,	NULL
respectively	NULL
,	NULL
which	NULL
were	NULL
pretreated	NULL
with	NULL
50-fold	NULL
excess	NULL
of	NULL
unlabeled	NULL
probe	NULL
.	NULL

B	NULL
,	NULL
AP-1	NULL
and	NULL
AP-1M	NULL
probes	NULL
.	NULL

Lanes	NULL
1	NULL
and	NULL
2	NULL
,	NULL
free	NULL
AP-1	NULL
and	NULL
AP-1M	NULL
probes	NULL
,	NULL
respectively	NULL
;	NULL
lames	NULL
3	NULL
and	NULL
5	NULL
,	NULL
untreated	NULL
and	NULL
OKT3-treated	NULL
extracts	NULL
,	NULL
respectively	NULL
,	NULL
probed	NULL
with	NULL
AP-1	NULL
probe	NULL
;	NULL
lanes	NULL
4	NULL
and	NULL
6	NULL
,	NULL
untreated	NULL
and	NULL
OKT3-treated	NULL
extracts	NULL
,	NULL
respectively	NULL
,	NULL
probed	NULL
with	NULL
AP-1M	NULL
probe	NULL
.	NULL

C	NULL
,	NULL
Sp1	NULL
probe	NULL
.	NULL

Lanes	NULL
1	NULL
and	NULL
2	NULL
,	NULL
untreated	NULL
and	NULL
OKT3-treated	NULL
extracts	NULL
,	NULL
respectively	NULL
;	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
,	NULL
untreated	NULL
and	NULL
OKT3-treated	NULL
extracts	NULL
,	NULL
respectively	NULL
,	NULL
which	NULL
were	NULL
pretreated	NULL
with	NULL
50-fold	NULL
excess	NULL
of	NULL
unlabeled	NULL
Spl	NULL
probe	NULL
;	NULL
lane	NULL
5	NULL
,	NULL
probe	NULL
alone	NULL
.	NULL

Arrows	NULL
indicate	NULL
specific	NULL
bands	NULL
.	NULL

differed	NULL
between	NULL
the	NULL
treatments	NULL
.	NULL

Results	NULL
presented	NULL
in	NULL
Fig	NULL
.	NULL

4C	NULL
show	NULL
the	NULL
relative	NULL
effectiveness	NULL
of	NULL
different	NULL
activating	NULL
agents	NULL
in	NULL
inducing	NULL
the	NULL
down-regulation	NULL
of	NULL
RXRa	NULL
mRNA	NULL
expression	NULL
.	NULL

The	NULL
Effect	NULL
of	NULL
OKT3-induced	NULL
Activation	NULL
on	NULL
DNA	NULL
Binding	NULL
Activity	NULL
of	NULL
RXRa-Retinoid	NULL
receptors	NULL
bind	NULL
to	NULL
specific	NULL
DNA	NULL
sequences	NULL
called	NULL
retinoic	NULL
acid	NULL
response	NULL
elements	NULL
(	NULL
RAREs	NULL
)	NULL
.	NULL

The	NULL
core	NULL
motif	NULL
of	NULL
these	NULL
RAREs	NULL
is	NULL
AGGTCA	NULL
.	NULL

Using	NULL
natural	NULL
and	NULL
synthetic	NULL
RAREs	NULL
,	NULL
it	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
RXRs	NULL
preferentially	NULL
bind	NULL
and	NULL
activate	NULL
direct	NULL
repeat	NULL
elements	NULL
in	NULL
which	NULL
core	NULL
motifs	NULL
are	NULL
separated	NULL
by	NULL
1	NULL
or	NULL
2	NULL
base	NULL
pairs	NULL
(	NULL
28-80	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
if	NULL
the	NULL
down-regulation	NULL
of	NULL
RXRa	NULL
levels	NULL
after	NULL
activation	NULL
were	NULL
reflected	NULL
in	NULL
a	NULL
comparable	NULL
difference	NULL
in	NULL
DNA	NULL
binding	NULL
activity	NULL
of	NULL
this	NULL
protein	NULL
,	NULL
the	NULL
DNA	NULL
binding	NULL
activity	NULL
was	NULL
studied	NULL
by	NULL
EMSA	NULL
using	NULL
oligonucleotides	NULL
corresponding	NULL
to	NULL
CRBPII	NULL
RXRE	NULL
.	NULL

As	NULL
can	NULL
be	NULL
seen	NULL
from	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
there	NULL
is	NULL
almost	NULL
complete	NULL
loss	NULL
of	NULL
DNA	NULL
binding	NULL
activity	NULL
after	NULL
the	NULL
treatment	NULL
of	NULL
PBMCs	NULL
with	NULL
OKT3	NULL
.	NULL

When	NULL
the	NULL
same	NULL
nuclear	NULL
extracts	NULL
were	NULL
analyzed	NULL
for	NULL
AP-1	NULL
binding	NULL
by	NULL
EMSA	NULL
,	NULL
there	NULL
was	NULL
6-fold	NULL
increase	NULL
in	NULL
the	NULL
AP-1	NULL
binding	NULL
activity	NULL
of	NULL
OKT3-treated	NULL
PBMCs	NULL
.	NULL

The	NULL
levels	NULL
of	NULL
a	NULL
constitutively	NULL
expressed	NULL
transcription	NULL
factor	NULL
Spl	NULL
(	NULL
31	NULL
)	NULL
showed	NULL
only	NULL
a	NULL
moderate	NULL
increase	NULL
(	NULL
less	NULL
than	NULL
2-fold	NULL
)	NULL
after	NULL
activation	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
integrity	NULL
and	NULL
the	NULL
amount	NULL
of	NULL
nuclear	NULL
extracts	NULL
derived	NULL
from	NULL
activated	NULL
PBMCs	NULL
were	NULL
comparable	NULL
with	NULL
that	NULL
from	NULL
untreated	NULL
cells	NULL
.	NULL

These	NULL
data	NULL
indicate	NULL
that	NULL
T	NULL
cell	NULL
activation	NULL
,	NULL
which	NULL
is	NULL
associated	NULL
with	NULL
a	NULL
marked	NULL
increase	NULL
in	NULL
AP-1	NULL
binding	NULL
activity	NULL
,	NULL
nevertheless	NULL
results	NULL
in	NULL
the	NULL
loss	NULL
of	NULL
RXR	NULL
binding	NULL
activity	NULL
.	NULL

Thus	NULL
,	NULL
activation-induced	NULL
loss	NULL
of	NULL
RXRa	NULL
mRNA	NULL
and	NULL
protein	NULL
expression	NULL
in	NULL
T	NULL
cells	NULL
correlates	NULL
with	NULL
the	NULL
loss	NULL
of	NULL
DNA	NULL
binding	NULL
activity	NULL
of	NULL
this	NULL
protein	NULL
.	NULL

Low	NULL
Level	NULL
Expression	NULL
of	NULL
RXRa	NULL
mRNA	NULL
Is	NULL
a	NULL
Feature	NULL
of	NULL
Actively	NULL
Dividing	NULL
T	NULL
Cells-To	NULL
study	NULL
the	NULL
fate	NULL
of	NULL
RXRa	NULL
mRNA	NULL
expression	NULL
in	NULL
actively	NULL
proliferating	NULL
human	NULL
T	NULL
cells	NULL
,	NULL
freshly	NULL
isolated	NULL
PBMCs	NULL
were	NULL
treated	NULL
with	NULL
PHA	NULL
and	NULL
IL2	NULL
for	NULL
3-4	NULL
days	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
washed	NULL
to	NULL
remove	NULL
the	NULL
PHA	NULL
and	NULL
maintained	NULL
in	NULL
IL2	NULL
.	NULL

Flow	NULL
cy-tometry	NULL
revealed	NULL
that	NULL
the	NULL
proliferating	NULL
cells	NULL
were	NULL
>	NULL
98	NULL
%	NULL
CD3*	NULL
T	NULL
lymphocytes	NULL
.	NULL

The	NULL
kinetics	NULL
of	NULL
alteration	NULL
of	NULL
RXRa	NULL
mRNA	NULL
expression	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
showed	NULL
75	NULL
%	NULL
down-regulation	NULL
after	NULL
4	NULL
days	NULL
of	NULL
PHA	NULL
+	NULL
IL2	NULL
treatment	NULL
(	NULL
when	NULL
the	NULL
cells	NULL
had	NULL
started	NULL
to	NULL
divide	NULL
)	NULL
,	NULL
and	NULL
by	NULL
day	NULL
10	NULL
when	NULL
the	NULL
cells	NULL
were	NULL
actively	NULL
proliferating	NULL
,	NULL
the	NULL
levels	NULL
of	NULL
RXRa	NULL
mRNA	NULL
had	NULL
reached	NULL
10	NULL
%	NULL
of	NULL
the	NULL
levels	NULL
seen	NULL
in	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
21214	NULL
100	NULL
100	NULL
80	NULL
-	NULL
p-	NULL
80	NULL
O	NULL
O	NULL
B	NULL
so	NULL
2	NULL
g	NULL
60	NULL
-	NULL
-	NULL
5	NULL
o	NULL
E	NULL
dd	NULL
E	NULL
g	NULL
40	NULL
-	NULL
|-	NULL
40	NULL
g	NULL
5	NULL
©	NULL
g	NULL
O	NULL
20	NULL
-	NULL
-	NULL
20	NULL
0	NULL
I	NULL
1	NULL
I	NULL
I	NULL
I	NULL
1	NULL
J	NULL
I	NULL
I	NULL
1	NULL
0	NULL
0	NULL
4	NULL
7	NULL
10	NULL
Day	NULL
Fic	NULL
.	NULL

6	NULL
.	NULL

RXRa	NULL
expression	NULL
during	NULL
T	NULL
cell	NULL
proliferation	NULL
.	NULL

5	NULL
X	NULL
10	NULL
``	NULL
PBMCs	NULL
(	NULL
10®/ml	NULL
)	NULL
were	NULL
treated	NULL
with	NULL
PHA	NULL
and	NULL
IL2	NULL
for	NULL
4	NULL
days	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
washed	NULL
twice	NULL
with	NULL
medium	NULL
to	NULL
remove	NULL
PHA	NULL
and	NULL
maintained	NULL
in	NULL
IL2	NULL
.	NULL

Cells	NULL
were	NULL
counted	NULL
,	NULL
and	NULL
RXRa	NULL
mRNA	NULL
expression	NULL
(	NULL
using	NULL
RT-PCR	NULL
)	NULL
was	NULL
quantitated	NULL
at	NULL
indicated	NULL
time	NULL
intervals	NULL
.	NULL

resting	NULL
cells	NULL
.	NULL

This	NULL
low	NULL
level	NULL
expression	NULL
of	NULL
RXRa	NULL
mRNA	NULL
was	NULL
maintained	NULL
throughout	NULL
T	NULL
cell	NULL
proliferation	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
the	NULL
expression	NULL
of	NULL
RXRa	NULL
:	NULL
in	NULL
T	NULL
lymphocytes	NULL
may	NULL
be	NULL
cell	NULL
cycle-regulated	NULL
.	NULL

Inhibition	NULL
of	NULL
Activation-induced	NULL
RXRa	NULL
Down-regulation	NULL
by	NULL
Inhibitors	NULL
of	NULL
T	NULL
Cell	NULL
Activation	NULL
and	NULL
Cell	NULL
Cycle	NULL
Regulation	NULL
of	NULL
RXRa	NULL
Expression-CsA	NULL
inhibits	NULL
T	NULL
cell	NULL
activation	NULL
by	NULL
inhibiting	NULL
calcineurin	NULL
(	NULL
a	NULL
Ca**/calmodulin-dependent	NULL
phosphatase	NULL
)	NULL
,	NULL
which	NULL
,	NULL
in	NULL
turn	NULL
,	NULL
inhibits	NULL
the	NULL
transcription	NULL
of	NULL
IL2	NULL
.	NULL

Because	NULL
the	NULL
binding	NULL
of	NULL
IL2	NULL
to	NULL
its	NULL
receptor	NULL
is	NULL
important	NULL
for	NULL
the	NULL
progression	NULL
from	NULL
the	NULL
G	NULL
,	NULL
to	NULL
the	NULL
S	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
(	NULL
82	NULL
)	NULL
,	NULL
signaling	NULL
through	NULL
the	NULL
IL2	NULL
receptor	NULL
is	NULL
inhibited	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
IL2	NULL
,	NULL
and	NULL
the	NULL
cells	NULL
are	NULL
prevented	NULL
from	NULL
entering	NULL
into	NULL
the	NULL
S	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

RAP	NULL
does	NULL
not	NULL
affect	NULL
the	NULL
production	NULL
of	NULL
IL2	NULL
but	NULL
does	NULL
inhibit	NULL
signals	NULL
transmitted	NULL
via	NULL
the	NULL
IL2	NULL
receptor	NULL
at	NULL
least	NULL
in	NULL
part	NULL
by	NULL
inhibiting	NULL
the	NULL
IL2-induced	NULL
phosphorylation	NULL
and	NULL
activation	NULL
of	NULL
p70°°*	NULL
(	NULL
83	NULL
)	NULL
.	NULL

In	NULL
the	NULL
presence	NULL
of	NULL
RAP	NULL
,	NULL
IL2-stimulated	NULL
T	NULL
cells	NULL
are	NULL
blocked	NULL
in	NULL
G	NULL
,	NULL
(	NULL
34	NULL
)	NULL
.	NULL

To	NULL
study	NULL
the	NULL
cell	NULL
cycle	NULL
regulation	NULL
of	NULL
RXRa	NULL
expression	NULL
in	NULL
T	NULL
cells	NULL
,	NULL
PBMCs	NULL
were	NULL
treated	NULL
with	NULL
OKT3	NULL
in	NULL
presence	NULL
of	NULL
CsA	NULL
or	NULL
RAP	NULL
.	NULL

Measurement	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
(	NULL
Fig	NULL
.	NULL

44	NULL
)	NULL
showed	NULL
that	NULL
both	NULL
CsA	NULL
and	NULL
RAP	NULL
inhibited	NULL
cellular	NULL
activation	NULL
induced	NULL
by	NULL
TCR-CD3	NULL
cross-linking	NULL
.	NULL

This	NULL
was	NULL
accompanied	NULL
by	NULL
inhibition	NULL
of	NULL
activation-induced	NULL
down-regulation	NULL
of	NULL
RXRa	NULL
mRNA	NULL
expression	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

CsA	NULL
was	NULL
more	NULL
effective	NULL
than	NULL
RAP	NULL
in	NULL
preventing	NULL
the	NULL
down-regulation	NULL
of	NULL
RXRa	NULL
mRNA	NULL
expression	NULL
induced	NULL
by	NULL
OKT3	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
CsA	NULL
inhibited	NULL
the	NULL
down-regulation	NULL
of	NULL
RXRa	NULL
mRNA	NULL
expression	NULL
induced	NULL
by	NULL
anti-TCR	NULL
af	NULL
antibody	NULL
(	NULL
Fig	NULL
.	NULL

4C	NULL
)	NULL
.	NULL

CsA	NULL
inhibition	NULL
of	NULL
OKT3-induced	NULL
RXRa	NULL
down-regulation	NULL
was	NULL
completely	NULL
prevented	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
IL2	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
IL2	NULL
may	NULL
be	NULL
necessary	NULL
for	NULL
the	NULL
activation-induced	NULL
decrease	NULL
in	NULL
RXRa	NULL
.	NULL

To	NULL
study	NULL
the	NULL
possibility	NULL
that	NULL
the	NULL
IL2	NULL
effect	NULL
may	NULL
be	NULL
mediated	NULL
by	NULL
regulation	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
,	NULL
we	NULL
treated	NULL
PBMCs	NULL
with	NULL
OKT3	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
mimosine	NULL
,	NULL
a	NULL
rare	NULL
plant	NULL
amino	NULL
acid	NULL
that	NULL
blocks	NULL
the	NULL
cell	NULL
cycle	NULL
at	NULL
the	NULL
G	NULL
;	NULL
phase	NULL
by	NULL
inhibiting	NULL
eukaryotic	NULL
initiation	NULL
factor	NULL
5-A	NULL
(	NULL
eIF5-A	NULL
)	NULL
(	NULL
35	NULL
)	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
,	NULL
either	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
IL2	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

7A	NULL
,	NULL
mimosine	NULL
completely	NULL
inhibited	NULL
the	NULL
OKT3-induced	NULL
down-regulation	NULL
of	NULL
RXRa	NULL
expression	NULL
.	NULL

IL2	NULL
had	NULL
no	NULL
effect	NULL
in	NULL
preventing	NULL
this	NULL
inhibition	NULL
.	NULL

Consistent	NULL
with	NULL
the	NULL
inability	NULL
of	NULL
IL2	NULL
to	NULL
release	NULL
the	NULL
G	NULL
;	NULL
block	NULL
induced	NULL
by	NULL
mimosine	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
,	NULL
the	NULL
inhibition	NULL
of	NULL
RXRa	NULL
down-regulation	NULL
could	NULL
not	NULL
be	NULL
prevented	NULL
by	NULL
treatment	NULL
with	NULL
IL2	NULL
.	NULL

These	NULL
data	NULL
indicate	NULL
that	NULL
the	NULL
cell	NULL
cycle	NULL
block	NULL
in	NULL
the	NULL
G	NULL
,	NULL
phase	NULL
Activation-induced	NULL
RXRa	NULL
Down-regulation	NULL
in	NULL
T	NULL
Lymphocytes	NULL
A	NULL
300	NULL
250-4	NULL
3	NULL
]	NULL
7,200-w	NULL
£	NULL
&	NULL
[	NULL
1504	NULL
T	NULL
8	NULL
i	NULL
1007	NULL
o	NULL
.	NULL

50-4	NULL
0-§	NULL
5	NULL
j	NULL
&	NULL
4	NULL
1	NULL
1	NULL
1	NULL
&	NULL
i	NULL
©	NULL
O	NULL
tC	NULL
Pa	NULL
+	NULL
+	NULL
o	NULL
[	NULL
es	NULL
Pa	NULL
i	NULL
$	NULL
°	NULL
$	NULL
$	NULL
$	NULL
i	NULL
G	NULL
e	NULL
500	NULL
tb	NULL
E	NULL
os	NULL
$	NULL
|	NULL
S	NULL
0	NULL
o	NULL
%	NULL
p	NULL
E	NULL
2	NULL
C	NULL
=	NULL
xX	NULL
O	NULL
x	NULL
O	NULL
&	NULL
C	NULL
o	NULL
B	NULL
%	NULL
Gy/G	NULL
;	NULL
+	NULL
94	NULL
_	NULL
80	NULL
T7	NULL
74	NULL
53	NULL
%	NULL
S-+	NULL
6	NULL
20	NULL
23	NULL
26	NULL
47	NULL
o	NULL
a	NULL
£7	NULL
§	NULL
$	NULL
é	NULL
Pi	NULL
iof	NULL
<	NULL
<	NULL
=	NULL
sr	NULL
&	NULL
S	NULL
3	NULL
5	NULL
|	NULL
|	NULL
]	NULL
]	NULL
]	NULL
Fic	NULL
.	NULL

7	NULL
.	NULL

Cell	NULL
cycle	NULL
regulation	NULL
of	NULL
RXRa	NULL
expression	NULL
in	NULL
PBMCs	NULL
and	NULL
proliferating	NULL
T	NULL
cells	NULL
.	NULL

A	NULL
,	NULL
PBMCs	NULL
(	NULL
10®/ml	NULL
)	NULL
were	NULL
treated	NULL
for	NULL
72	NULL
h	NULL
as	NULL
indicated	NULL
.	NULL

RXRa	NULL
mRNA	NULL
was	NULL
quantitated	NULL
by	NULL
RT-PCR	NULL
.	NULL

B	NULL
,	NULL
7-10-day-old	NULL
proliferating	NULL
peripheral	NULL
T	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
100	NULL
ug/ml	NULL
mimosine	NULL
for	NULL
24	NULL
h.	NULL
Cells	NULL
were	NULL
washed	NULL
three	NULL
times	NULL
with	NULL
medium	NULL
to	NULL
remove	NULL
mimosine	NULL
and	NULL
cultured	NULL
in	NULL
fresh	NULL
medium	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
after	NULL
indicated	NULL
time	NULL
periods	NULL
,	NULL
and	NULL
dead	NULL
cells	NULL
were	NULL
removed	NULL
by	NULL
Ficoll	NULL
gradient	NULL
centrifugation	NULL
.	NULL

Cell	NULL
cycle	NULL
analysis	NULL
was	NULL
performed	NULL
,	NULL
and	NULL
RXRa	NULL
mRNA	NULL
level	NULL
was	NULL
estimated	NULL
by	NULL
RT-PCR	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
.	NULL
``	NULL

TaBLE	NULL
I	NULL
Cell	NULL
cycle	NULL
analysis	NULL
of	NULL
CsA	NULL
and	NULL
mimosine-treated	NULL
PBMCs	NULL
PBMCs	NULL
fare	NULL
C	NULL
,	NULL
s	NULL
%	NULL
Untreated	NULL
94.7	NULL
3.2	NULL
2.1	NULL
OKT3	NULL
74.8	NULL
4.7	NULL
21	NULL
OKT3	NULL
+	NULL
CsA	NULL
97.8	NULL
0.3	NULL
1.9	NULL
OKT3	NULL
+	NULL
CsA	NULL
+	NULL
IL2	NULL
75.3	NULL
5.6	NULL
19.1	NULL
OKT3	NULL
+	NULL
mimosine	NULL
95.7	NULL
2.1	NULL
2.2	NULL
OKT3	NULL
+	NULL
mimosine	NULL
+	NULL
IL2	NULL
94.3	NULL
5.7	NULL
0	NULL
accounted	NULL
for	NULL
the	NULL
inhibition	NULL
of	NULL
activation-induced	NULL
down-regulation	NULL
induced	NULL
by	NULL
CsA	NULL
,	NULL
RAP	NULL
,	NULL
and	NULL
mimosine	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
effect	NULL
of	NULL
IL2	NULL
in	NULL
preventing	NULL
the	NULL
CsA-induced	NULL
inhibition	NULL
of	NULL
RXRa	NULL
down-regulation	NULL
was	NULL
correlated	NULL
to	NULL
the	NULL
release	NULL
of	NULL
the	NULL
CsA-induced	NULL
G	NULL
,	NULL
block	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
.	NULL

Further	NULL
proof	NULL
that	NULL
the	NULL
levels	NULL
of	NULL
RXRa	NULL
are	NULL
cell	NULL
cycle-regulated	NULL
came	NULL
from	NULL
the	NULL
experiment	NULL
in	NULL
which	NULL
actively	NULL
dividing	NULL
peripheral	NULL
T	NULL
lymphocytes	NULL
,	NULL
which	NULL
express	NULL
low	NULL
levels	NULL
of	NULL
RXRa	NULL
mRNA	NULL
as	NULL
compared	NULL
with	NULL
the	NULL
resting	NULL
cells	NULL
,	NULL
were	NULL
treated	NULL
with	NULL
mimosine	NULL
for	NULL
24	NULL
h.	NULL
Treatment	NULL
with	NULL
mimosine	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
Activation-induced	NULL
RXRa	NULL
Down-regulation	NULL
in	NULL
T	NULL
Lymphocytes	NULL
D	NULL
D	NULL
-actin	NULL
<	NULL
=	NULL
RXRo	NULL
:	NULL
Fig	NULL
.	NULL

8	NULL
.	NULL

Nuclear	NULL
run-on	NULL
analysis	NULL
.	NULL

Transcriptional	NULL
analysis	NULL
was	NULL
performed	NULL
with	NULL
untreated	NULL
and	NULL
OKT3-treated	NULL
PBMCs	NULL
(	NULL
A	NULL
)	NULL
and	NULL
mimosine-treated	NULL
and	NULL
9-h	NULL
released	NULL
peripheral	NULL
T	NULL
cells	NULL
(	NULL
B	NULL
)	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
``	NULL
using	NULL
indicated	NULL
linearized	NULL
plasmids	NULL
.	NULL

Vector	NULL
without	NULL
the	NULL
insert	NULL
was	NULL
used	NULL
as	NULL
a	NULL
negative	NULL
control	NULL
.	NULL

This	NULL
experiment	NULL
is	NULL
a	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

blocked	NULL
the	NULL
cells	NULL
in	NULL
G	NULL
,	NULL
phase	NULL
and	NULL
resulted	NULL
in	NULL
a	NULL
marked	NULL
up-regulation	NULL
of	NULL
RXRa	NULL
mRNA	NULL
.	NULL

When	NULL
the	NULL
mimosine	NULL
block	NULL
was	NULL
released	NULL
to	NULL
allow	NULL
progression	NULL
into	NULL
the	NULL
cell	NULL
cycle	NULL
,	NULL
the	NULL
levels	NULL
of	NULL
RXRa	NULL
mRNA	NULL
decreased	NULL
progressively	NULL
and	NULL
,	NULL
in	NULL
24	NULL
h	NULL
after	NULL
re-lease	NULL
,	NULL
reached	NULL
the	NULL
levels	NULL
seen	NULL
in	NULL
actively	NULL
cycling	NULL
untreated	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
)	NULL
.	NULL

Regulation	NULL
of	NULL
RXRa	NULL
mRNA	NULL
Expression	NULL
during	NULL
Cell	NULL
Cy-cle-To	NULL
study	NULL
the	NULL
involvement	NULL
of	NULL
transcriptional	NULL
or	NULL
post-tran-scriptional	NULL
factors	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
RXRa	NULL
mRNA	NULL
expression	NULL
during	NULL
T	NULL
cell	NULL
activation	NULL
and	NULL
transition	NULL
from	NULL
G/G	NULL
;	NULL
to	NULL
the	NULL
S	NULL
phase	NULL
,	NULL
we	NULL
measured	NULL
the	NULL
transcription	NULL
of	NULL
RXRa	NULL
mRNA	NULL
in	NULL
OKT3-treated	NULL
PBMCs	NULL
and	NULL
mimosine-blocked	NULL
and	NULL
-released	NULL
proliferating	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
,	NULL
using	NULL
nuclear	NULL
run-on	NULL
transcription	NULL
assay	NULL
.	NULL

The	NULL
results	NULL
indicate	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
that	NULL
the	NULL
levels	NULL
of	NULL
RXRa	NULL
mRNA	NULL
synthesis	NULL
show	NULL
only	NULL
moderate	NULL
(	NULL
less	NULL
than	NULL
2-fold	NULL
)	NULL
increase	NULL
during	NULL
G/G	NULL
,	NULL
block	NULL
.	NULL

Next	NULL
,	NULL
we	NULL
analyzed	NULL
the	NULL
effect	NULL
of	NULL
actinomycin	NULL
D	NULL
and	NULL
cycloheximide	NULL
on	NULL
the	NULL
loss	NULL
of	NULL
RXRa	NULL
mRNA	NULL
levels	NULL
during	NULL
mimosine	NULL
release	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

9	NULL
,	NULL
Act	NULL
D	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
kinetics	NULL
of	NULL
RXRa	NULL
mRNA	NULL
down-regulation	NULL
during	NULL
mimosine	NULL
release	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
when	NULL
mimosine	NULL
release	NULL
was	NULL
carried	NULL
out	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
CHX	NULL
,	NULL
there	NULL
was	NULL
a	NULL
marked	NULL
inhibition	NULL
of	NULL
RXRa	NULL
mRNA	NULL
down-regulation	NULL
.	NULL

Together	NULL
,	NULL
these	NULL
data	NULL
suggest	NULL
that	NULL
the	NULL
loss	NULL
of	NULL
RXRa	NULL
mRNA	NULL
expression	NULL
during	NULL
G/G	NULL
;	NULL
to	NULL
S	NULL
transition	NULL
is	NULL
partly	NULL
due	NULL
to	NULL
the	NULL
decrease	NULL
in	NULL
the	NULL
gene	NULL
transcription	NULL
but	NULL
is	NULL
primarily	NULL
a	NULL
result	NULL
of	NULL
decreased	NULL
mRNA	NULL
stability	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
CHX	NULL
may	NULL
block	NULL
the	NULL
synthesis	NULL
of	NULL
post-transcrip-tional	NULL
regulatory	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
capable	NULL
of	NULL
modulating	NULL
the	NULL
RXRa	NULL
mRNA	NULL
levels	NULL
during	NULL
G/G	NULL
;	NULL
to	NULL
S	NULL
transition	NULL
.	NULL

DISCUSSION	NULL
Although	NULL
there	NULL
is	NULL
a	NULL
growing	NULL
list	NULL
of	NULL
genes	NULL
that	NULL
are	NULL
known	NULL
to	NULL
be	NULL
up-regulated	NULL
after	NULL
T	NULL
cell	NULL
activation	NULL
(	NULL
1	NULL
)	NULL
,	NULL
there	NULL
are	NULL
only	NULL
a	NULL
few	NULL
that	NULL
are	NULL
known	NULL
to	NULL
be	NULL
inhibited	NULL
after	NULL
activation	NULL
(	NULL
36-38	NULL
)	NULL
.	NULL

We	NULL
have	NULL
utilized	NULL
the	NULL
DD-RT-PCR	NULL
technique	NULL
to	NULL
identify	NULL
and	NULL
analyze	NULL
the	NULL
genes	NULL
involved	NULL
in	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

In	NULL
this	NULL
paper	NULL
,	NULL
we	NULL
chose	NULL
to	NULL
characterize	NULL
one	NULL
such	NULL
gene	NULL
and	NULL
have	NULL
identified	NULL
the	NULL
newly	NULL
isolated	NULL
sequence	NULL
as	NULL
the	NULL
unpublished	NULL
3	NULL
'	NULL
end	NULL
of	NULL
the	NULL
5.4-kb	NULL
human	NULL
RXRa	NULL
mRNA	NULL
.	NULL

We	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
activation	NULL
of	NULL
PBMCs	NULL
resulted	NULL
in	NULL
the	NULL
down-regulation	NULL
of	NULL
RXRa	NULL
mRNA	NULL
,	NULL
protein	NULL
,	NULL
and	NULL
DNA	NULL
binding	NULL
activity	NULL
.	NULL

The	NULL
extent	NULL
of	NULL
RXRa	NULL
mRNA	NULL
down-regulation	NULL
differed	NULL
between	NULL
the	NULL
activating	NULL
agents	NULL
;	NULL
the	NULL
21215	NULL
1000	NULL
7	NULL
-e-	NULL
Untreated	NULL
~e~	NULL
Act	NULL
D	NULL
Phosphorimager	NULL
Units	NULL
(	NULL
Log	NULL
)	NULL
3	NULL
O	NULL
iad	NULL
10	NULL
T	NULL
T	NULL
T	NULL
0	NULL
6	NULL
9	NULL
Time	NULL
(	NULL
Hrs	NULL
)	NULL
after	NULL
Mimosine	NULL
Release	NULL
Fic	NULL
.	NULL

9	NULL
.	NULL

Effect	NULL
of	NULL
Act	NULL
D	NULL
and	NULL
CHX	NULL
on	NULL
the	NULL
RXRa	NULL
mRNA	NULL
down-regulation	NULL
during	NULL
G	NULL
,	NULL
to	NULL
S	NULL
switch	NULL
.	NULL

Peripheral	NULL
blood	NULL
T	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
mimosine	NULL
as	NULL
described	NULL
.	NULL

Cells	NULL
were	NULL
washed	NULL
to	NULL
remove	NULL
mimosine	NULL
and	NULL
maintained	NULL
in	NULL
IL2	NULL
in	NULL
presence	NULL
of	NULL
Act	NULL
D	NULL
or	NULL
CHX	NULL
as	NULL
described	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
after	NULL
the	NULL
indicated	NULL
time	NULL
intervals	NULL
,	NULL
and	NULL
RXRa	NULL
mRNA	NULL
was	NULL
quantitated	NULL
by	NULL
RT-PCR	NULL
.	NULL

The	NULL
values	NULL
represent	NULL
the	NULL
mean	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
with	NULL
standard	NULL
error	NULL
calculated	NULL
for	NULL
each	NULL
value	NULL
.	NULL

most	NULL
effective	NULL
were	NULL
those	NULL
that	NULL
induced	NULL
maximum	NULL
activation	NULL
.	NULL

These	NULL
data	NULL
demonstrate	NULL
that	NULL
down-regulation	NULL
of	NULL
RXRa	NULL
mRNA	NULL
expression	NULL
is	NULL
an	NULL
event	NULL
associated	NULL
with	NULL
the	NULL
T	NULL
cell	NULL
activation	NULL
induced	NULL
by	NULL
a	NULL
variety	NULL
of	NULL
stimuli	NULL
,	NULL
and	NULL
the	NULL
level	NULL
of	NULL
down-regulation	NULL
reflects	NULL
the	NULL
extent	NULL
of	NULL
cellular	NULL
activation	NULL
.	NULL

The	NULL
finding	NULL
that	NULL
the	NULL
low	NULL
levels	NULL
of	NULL
RXRa	NULL
are	NULL
maintained	NULL
throughout	NULL
active	NULL
T	NULL
cell	NULL
proliferation	NULL
as	NULL
compared	NULL
with	NULL
the	NULL
resting	NULL
cells	NULL
is	NULL
consistent	NULL
with	NULL
the	NULL
possibility	NULL
of	NULL
cell	NULL
cycle	NULL
regulation	NULL
of	NULL
RXRa	NULL
expression	NULL
.	NULL

The	NULL
activation-induced	NULL
down-regulation	NULL
of	NULL
RXRa	NULL
mRNA	NULL
expression	NULL
was	NULL
inhibited	NULL
by	NULL
agents	NULL
that	NULL
blocked	NULL
the	NULL
cells	NULL
in	NULL
G	NULL
,	NULL
phase	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
cell	NULL
cycle	NULL
block	NULL
in	NULL
G	NULL
,	NULL
phase	NULL
accounted	NULL
for	NULL
such	NULL
inhibition	NULL
.	NULL

Because	NULL
IL2	NULL
prevented	NULL
only	NULL
the	NULL
CsA	NULL
but	NULL
not	NULL
the	NULL
mimosine-induced	NULL
inhibition	NULL
of	NULL
RXRa	NULL
down-regulation	NULL
by	NULL
OKT3	NULL
,	NULL
we	NULL
suspect	NULL
that	NULL
the	NULL
IL2	NULL
effect	NULL
is	NULL
most	NULL
likely	NULL
mediated	NULL
by	NULL
the	NULL
regulation	NULL
of	NULL
cell	NULL
cycle	NULL
(	NULL
through	NULL
the	NULL
release	NULL
of	NULL
the	NULL
CsA-induced	NULL
G	NULL
,	NULL
block	NULL
)	NULL
.	NULL

Our	NULL
conclusion	NULL
that	NULL
the	NULL
RXRa	NULL
mRNA	NULL
levels	NULL
are	NULL
cell	NULL
cycle	NULL
regulated	NULL
is	NULL
further	NULL
supported	NULL
by	NULL
the	NULL
studies	NULL
on	NULL
the	NULL
effect	NULL
of	NULL
mimosine	NULL
on	NULL
actively	NULL
dividing	NULL
peripheral	NULL
T	NULL
lymphocytes	NULL
,	NULL
where	NULL
large	NULL
populations	NULL
of	NULL
cells	NULL
were	NULL
in	NULL
S	NULL
phase	NULL
and	NULL
RXRa	NULL
levels	NULL
were	NULL
low	NULL
.	NULL

Mimosine	NULL
inhibited	NULL
proliferation	NULL
,	NULL
blocked	NULL
the	NULL
cells	NULL
in	NULL
the	NULL
G	NULL
;	NULL
phase	NULL
,	NULL
and	NULL
resulted	NULL
in	NULL
significant	NULL
up-regulation	NULL
of	NULL
RXRa	NULL
mRNA	NULL
.	NULL

The	NULL
release	NULL
of	NULL
mimosine-induced	NULL
G	NULL
;	NULL
block	NULL
was	NULL
accompanied	NULL
by	NULL
progression	NULL
into	NULL
cell	NULL
cycle	NULL
and	NULL
a	NULL
progressive	NULL
loss	NULL
of	NULL
RXRa	NULL
mRNA	NULL
expression	NULL
.	NULL

The	NULL
molecular	NULL
mechanism	NULL
of	NULL
activation-induced	NULL
down-regulation	NULL
of	NULL
RXRa	NULL
mRNA	NULL
remains	NULL
unknown	NULL
.	NULL

The	NULL
data	NULL
obtained	NULL
on	NULL
the	NULL
role	NULL
of	NULL
transcriptional	NULL
and	NULL
postranscriptional	NULL
mechanisms	NULL
in	NULL
regulating	NULL
the	NULL
levels	NULL
of	NULL
RXRa	NULL
mRNA	NULL
during	NULL
T	NULL
cell	NULL
activation	NULL
and	NULL
G	NULL
;	NULL
to	NULL
S	NULL
switch	NULL
show	NULL
that	NULL
the	NULL
down-regulation	NULL
of	NULL
RXRa	NULL
mRNA	NULL
is	NULL
primarily	NULL
the	NULL
result	NULL
of	NULL
a	NULL
decrease	NULL
in	NULL
the	NULL
mRNA	NULL
stability	NULL
and	NULL
partly	NULL
the	NULL
result	NULL
of	NULL
a	NULL
decrease	NULL
in	NULL
the	NULL
gene	NULL
tran-scription	NULL
;	NULL
new	NULL
protein	NULL
synthesis	NULL
is	NULL
required	NULL
to	NULL
accomplish	NULL
this	NULL
.	NULL

The	NULL
-untranslated	NULL
sequence	NULL
of	NULL
RX	NULL
Ra	NULL
mRNA	NULL
contains	NULL
a	NULL
single	NULL
copy	NULL
of	NULL
AUUUA	NULL
sequence	NULL
.	NULL

This	NULL
sequence	NULL
has	NULL
been	NULL
identified	NULL
as	NULL
the	NULL
mRNA	NULL
instability	NULL
signal	NULL
involved	NULL
in	NULL
the	NULL
mRNA	NULL
decay	NULL
(	NULL
39	NULL
)	NULL
.	NULL

Whereas	NULL
the	NULL
role	NULL
of	NULL
this	NULL
sequence	NULL
in	NULL
the	NULL
stability	NULL
of	NULL
RXRa	NULL
mRNA	NULL
remains	NULL
to	NULL
be	NULL
studied	NULL
,	NULL
this	NULL
sequence	NULL
alone	NULL
may	NULL
not	NULL
account	NULL
for	NULL
the	NULL
RXRa	NULL
mRNA	NULL
destabilization	NULL
during	NULL
Gy/G	NULL
;	NULL
to	NULL
S	NULL
switch	NULL
.	NULL

610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
21216	NULL
Together	NULL
,	NULL
our	NULL
data	NULL
indicate	NULL
that	NULL
the	NULL
levels	NULL
of	NULL
RXRa	NULL
expression	NULL
in	NULL
T	NULL
lymphocytes	NULL
are	NULL
coupled	NULL
to	NULL
cell	NULL
cycle	NULL
progression	NULL
,	NULL
and	NULL
there	NULL
is	NULL
tight	NULL
regulatory	NULL
control	NULL
of	NULL
RX	NULL
Ra	NULL
expression	NULL
during	NULL
the	NULL
transition	NULL
from	NULL
G/G	NULL
,	NULL
to	NULL
S	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

RXRs	NULL
along	NULL
with	NULL
RARs	NULL
have	NULL
the	NULL
ability	NULL
to	NULL
silence	NULL
transcription	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
ligand	NULL
(	NULL
40	NULL
)	NULL
.	NULL

It	NULL
is	NULL
known	NULL
that	NULL
T	NULL
cell	NULL
activation	NULL
induces	NULL
expression	NULL
of	NULL
transcription	NULL
factor	NULL
AP-1	NULL
(	NULL
41	NULL
,	NULL
42	NULL
)	NULL
.	NULL

Retinoid	NULL
receptors	NULL
regulate	NULL
transcriptional	NULL
activation	NULL
either	NULL
through	NULL
receptor-DNA	NULL
interactions	NULL
or	NULL
by	NULL
inhibiting	NULL
AP-1	NULL
(	NULL
13	NULL
)	NULL
.	NULL

It	NULL
can	NULL
be	NULL
speculated	NULL
that	NULL
the	NULL
levels	NULL
of	NULL
RXRa	NULL
in	NULL
resting	NULL
T	NULL
lymphocytes	NULL
are	NULL
inhibitory	NULL
to	NULL
AP-1	NULL
activity	NULL
and	NULL
prevent	NULL
AP-1-induced	NULL
gene	NULL
transcription	NULL
and	NULL
proliferation	NULL
.	NULL

Thus	NULL
,	NULL
RXRa	NULL
may	NULL
play	NULL
an	NULL
important	NULL
role	NULL
by	NULL
providing	NULL
a	NULL
switch	NULL
that	NULL
allows	NULL
operation	NULL
of	NULL
a	NULL
signaling	NULL
system	NULL
that	NULL
controls	NULL
fine	NULL
tuning	NULL
of	NULL
regulation	NULL
of	NULL
T	NULL
cell	NULL
proliferation	NULL
.	NULL

Recent	NULL
data	NULL
suggest	NULL
that	NULL
RXRs	NULL
may	NULL
have	NULL
a	NULL
role	NULL
in	NULL
the	NULL
prevention	NULL
of	NULL
activation-induced	NULL
apoptosis	NULL
in	NULL
T	NULL
cell	NULL
hybridomas	NULL
and	NULL
thymocytes	NULL
(	NULL
14-17	NULL
)	NULL
.	NULL

It	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
activation-induced	NULL
apoptosis	NULL
can	NULL
be	NULL
prevented	NULL
by	NULL
treatment	NULL
with	NULL
9-cis	NULL
retinoic	NULL
acid	NULL
,	NULL
a	NULL
ligand	NULL
that	NULL
has	NULL
very	NULL
high	NULL
affinity	NULL
for	NULL
the	NULL
RXR	NULL
receptor	NULL
(	NULL
16	NULL
,	NULL
17	NULL
)	NULL
.	NULL

These	NULL
findings	NULL
,	NULL
together	NULL
with	NULL
our	NULL
results	NULL
,	NULL
point	NULL
to	NULL
a	NULL
role	NULL
of	NULL
RXRs	NULL
in	NULL
general	NULL
and	NULL
RXRa	NULL
in	NULL
particular	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
T	NULL
lymphocyte	NULL
activation	NULL
,	NULL
proliferation	NULL
,	NULL
and	NULL
cell	NULL
death	NULL
.	NULL

Acknowledgments-We	NULL
are	NULL
thankful	NULL
to	NULL
Ming	NULL
Fan	NULL
,	NULL
Lysa	NULL
Baginsky	NULL
,	NULL
Dennis	NULL
O	NULL
'	NULL
Neill	NULL
,	NULL
Edward	NULL
Scott	NULL
,	NULL
Allison	NULL
Hazen	NULL
,	NULL
and	NULL
Marjorie	NULL
Bosche	NULL
for	NULL
their	NULL
technical	NULL
help	NULL
;	NULL
Dr.	NULL
M.	NULL
Baseler	NULL
and	NULL
his	NULL
technical	NULL
staff	NULL
for	NULL
their	NULL
help	NULL
in	NULL
flow	NULL
cytometry	NULL
;	NULL
Julie	NULL
Metcalf	NULL
for	NULL
providing	NULL
blood	NULL
samples	NULL
;	NULL
and	NULL
Dr.	NULL
H.	NULL
Clifford	NULL
Lane	NULL
and	NULL
Dr.	NULL
Robin	NULL
Dewar	NULL
for	NULL
critically	NULL
reading	NULL
the	NULL
manuscript	NULL
and	NULL
providing	NULL
valuable	NULL
suggestions	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Ullman	NULL
,	NULL
K.	NULL
S.	NULL
,	NULL
Northrop	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Verweij	NULL
,	NULL
C.	NULL
L.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1990	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

8	NULL
,	NULL
421-452	NULL
.	NULL

Berridge	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
and	NULL
Irvine	NULL
,	NULL
R.	NULL
F.	NULL
(	NULL
1984	NULL
)	NULL
Nature	NULL
812	NULL
,	NULL
815-321	NULL
.	NULL

Imboden	NULL
,	NULL
J.	NULL
,	NULL
Weiss	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Stobo	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
6	NULL
,	NULL
328-831	NULL
.	NULL

Van	NULL
Wauwe	NULL
,	NULL
J.	NULL
,	NULL
De	NULL
Mey	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Goossens	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1980	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

124	NULL
,	NULL
2708-2713	NULL
5	NULL
.	NULL

Chang	NULL
,	NULL
T.	NULL
,	NULL
Kung	NULL
,	NULL
P.	NULL
C.	NULL
,	NULL
Gingras	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Goldstein	NULL
,	NULL
G.	NULL
(	NULL
1981	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

78	NULL
,	NULL
1805-1808	NULL
6.	NULL
von	NULL
Wussow	NULL
,	NULL
P.	NULL
,	NULL
Platsoucas	NULL
,	NULL
C.	NULL
D.	NULL
,	NULL
Wiranowska-	NULL
Stewart	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Stewart	NULL
,	NULL
W.	NULL
E.	NULL
,	NULL
II	NULL
(	NULL
1981	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

127	NULL
,	NULL
1197-2000	NULL
7	NULL
.	NULL

Kurrle	NULL
,	NULL
R.	NULL
,	NULL
Schorlemmer	NULL
,	NULL
C.	NULL
,	NULL
Shearman	NULL
,	NULL
L.	NULL
,	NULL
Lauffer	NULL
,	NULL
L.	NULL
,	NULL
Frank	NULL
,	NULL
K.	NULL
,	NULL
Kanzy	NULL
,	NULL
E.	NULL
J.	NULL
,	NULL
and	NULL
Seiler	NULL
,	NULL
F.	NULL
R.	NULL
(	NULL
1991	NULL
)	NULL
Transplant	NULL
.	NULL

Proc	NULL
.	NULL

28	NULL
,	NULL
272-276	NULL
8	NULL
.	NULL

Meuer	NULL
,	NULL
S.	NULL
C.	NULL
,	NULL
Hussey	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
Fabbi	NULL
,	NULL
M.	NULL
,	NULL
Fox	NULL
,	NULL
D.	NULL
,	NULL
Acuto	NULL
,	NULL
O.	NULL
,	NULL
Fitzgerald	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
Hodgon	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Potentis	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Schlossman	NULL
,	NULL
S.	NULL
F.	NULL
,	NULL
and	NULL
Reinherz	NULL
.	NULL

E.	NULL
L.	NULL
(	NULL
1984	NULL
)	NULL
Cell	NULL
86	NULL
,	NULL
897-906	NULL
9	NULL
.	NULL

Coligan	NULL
,	NULL
J.	NULL
E.	NULL
,	NULL
Kruisbeck	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
Margulies	NULL
,	NULL
D.	NULL
H.	NULL
,	NULL
Shevach	NULL
,	NULL
E.	NULL
M.	NULL
,	NULL
and	NULL
Strober	NULL
,	NULL
#	NULL
>	NULL
00	NULL
bo	NULL
29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32.	NULL
.	NULL

Schreiber	NULL
,	NULL
S.	NULL
L.	NULL
(	NULL
1992	NULL
)	NULL
Cell	NULL
70	NULL
,	NULL
365-368	NULL
34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39.	NULL
.	NULL

Tsai	NULL
,	NULL
M.-J	NULL
.	NULL

,	NULL
and	NULL
O	NULL
'	NULL
Malley	NULL
,	NULL
B.	NULL
W.	NULL
(	NULL
1994	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Biochem	NULL
.	NULL

68	NULL
,	NULL
451-486	NULL
41	NULL
.	NULL

42	NULL
.	NULL

Activation-induced	NULL
RXRa	NULL
Down-regulation	NULL
in	NULL
T	NULL
Lymphocytes	NULL
W.	NULL
(	NULL
1992	NULL
)	NULL
Current	NULL
Protocols	NULL
in	NULL
Immunology	NULL
,	NULL
Vol	NULL
.	NULL

2	NULL
,	NULL
pp	NULL
.	NULL

7.10.1-7.10.10	NULL
,	NULL
John	NULL
Wiley	NULL
&	NULL
Sons	NULL
,	NULL
Inc.	NULL
,	NULL
New	NULL
York	NULL
.	NULL

Lindsten	NULL
,	NULL
T.	NULL
,	NULL
June	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
and	NULL
Thompson	NULL
,	NULL
C.	NULL
B	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

7	NULL
,	NULL
2787-2794	NULL
.	NULL

Mangelsdorf	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Man	NULL
,	NULL
J.	NULL
,	NULL
Kliewer	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
Kakizuka	NULL
,	NULL
A.	NULL
,	NULL
Umesono	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Evans	NULL
,	NULL
R.	NULL
M.	NULL
(	NULL
19983	NULL
)	NULL
Recent	NULL
Prog	NULL
.	NULL

Horm	NULL
.	NULL

Res	NULL
.	NULL

48	NULL
,	NULL
99-121	NULL
.	NULL

Mangelsdorf	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
and	NULL
Evans	NULL
,	NULL
R.	NULL
M.	NULL
(	NULL
1995	NULL
)	NULL
Cell	NULL
88	NULL
,	NULL
841-850	NULL
.	NULL

Pfah	NULL
]	NULL
,	NULL
M.	NULL
(	NULL
1993	NULL
)	NULL
Endocr	NULL
.	NULL

Rev	NULL
.	NULL

14	NULL
,	NULL
651-658	NULL
.	NULL

Iwata	NULL
,	NULL
M.	NULL
,	NULL
Mukai	NULL
,	NULL
M.	NULL
,	NULL
Nakai	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
Iseki	NULL
,	NULL
R.	NULL
(	NULL
1992	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

149	NULL
,	NULL
3302-3308	NULL
.	NULL

Yang	NULL
,	NULL
Y.	NULL
,	NULL
Vacchio	NULL
,	NULL
M.	NULL
S.	NULL
,	NULL
and	NULL
Ashwell	NULL
,	NULL
J.	NULL
D.	NULL
(	NULL
1993	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

90	NULL
,	NULL
6170-6174	NULL
.	NULL

Yang	NULL
,	NULL
Y.	NULL
,	NULL
Mercep	NULL
,	NULL
M.	NULL
,	NULL
Ware	NULL
,	NULL
C.	NULL
F.	NULL
,	NULL
and	NULL
Ashwell	NULL
,	NULL
J.	NULL
D.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

181	NULL
,	NULL
1673-1682	NULL
.	NULL

Bissonnette	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
Brunner	NULL
,	NULL
T.	NULL
,	NULL
Lazarchik	NULL
,	NULL
S.	NULL
B.	NULL
,	NULL
Yoo	NULL
,	NULL
N.	NULL
M.	NULL
,	NULL
Bochm	NULL
,	NULL
M.	NULL
F.	NULL
,	NULL
Green	NULL
,	NULL
D.	NULL
R.	NULL
,	NULL
and	NULL
Heyman	NULL
,	NULL
R.	NULL
A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15	NULL
,	NULL
5576-5585	NULL
.	NULL

Liang	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Pardee	NULL
,	NULL
A	NULL
.	NULL

B	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Science	NULL
257	NULL
,	NULL
967-971	NULL
.	NULL

Welsh	NULL
,	NULL
J.	NULL
,	NULL
Chada	NULL
,	NULL
K.	NULL
,	NULL
Dalal	NULL
,	NULL
S.	NULL
S.	NULL
,	NULL
Cheng	NULL
,	NULL
R.	NULL
,	NULL
Dalph	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
McClelland	NULL
M.	NULL
(	NULL
1992	NULL
)	NULL
Arbitrarily	NULL
primed	NULL
PCR	NULL
fingerprinting	NULL
of	NULL
RNA	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

20	NULL
,	NULL
4965-4970	NULL
.	NULL

McClelland	NULL
,	NULL
M.	NULL
,	NULL
Mathien-Daude	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
Welsh	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Trends	NULL
Genet	NULL
.	NULL

11	NULL
,	NULL
242-246	NULL
.	NULL

Shen	NULL
,	NULL
R.	NULL
,	NULL
Su	NULL
,	NULL
Z-Z	NULL
.	NULL

,	NULL
Olsson	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
and	NULL
Fisher	NULL
,	NULL
P.	NULL
B	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

92	NULL
,	NULL
6778-6782	NULL
.	NULL

Liang	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Pardee	NULL
,	NULL
A	NULL
.	NULL

B	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Curr	NULL
.	NULL

Opin	NULL
.	NULL

Immunol	NULL
.	NULL

7	NULL
,	NULL
274-280	NULL
.	NULL

Frohman	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Dush	NULL
,	NULL
M.	NULL
K.	NULL
,	NULL
and	NULL
Martin	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1988	NULL
)	NULL
Proc	NULL
.	NULL

Na	NULL
#	NULL
l	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

85	NULL
,	NULL
8998-9002	NULL
.	NULL

Mangelsdorf	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Ong	NULL
,	NULL
E.	NULL
S.	NULL
,	NULL
Dyck	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
Evans	NULL
,	NULL
R.	NULL
M.	NULL
(	NULL
1990	NULL
)	NULL
Nature	NULL
845	NULL
,	NULL
224-229	NULL
.	NULL

McCallum	NULL
,	NULL
F.	NULL
S.	NULL
,	NULL
and	NULL
Maden	NULL
,	NULL
B.	NULL
E.	NULL
H.	NULL
(	NULL
1985	NULL
)	NULL
Biochem	NULL
.	NULL

J	NULL
.	NULL

282	NULL
,	NULL
725-733	NULL
.	NULL

Nikaido	NULL
,	NULL
T.	NULL
,	NULL
Shimizu	NULL
,	NULL
A.	NULL
,	NULL
Ishida	NULL
,	NULL
N.	NULL
,	NULL
Sabe	NULL
,	NULL
H.	NULL
,	NULL
Teshigawara	NULL
,	NULL
K.	NULL
,	NULL
Maeda	NULL
,	NULL
M.	NULL
,	NULL
Uchiyama	NULL
,	NULL
T.	NULL
,	NULL
Yodoi	NULL
,	NULL
T.	NULL
J.	NULL
,	NULL
and	NULL
Honjo	NULL
,	NULL
T.	NULL
(	NULL
1984	NULL
)	NULL
Nature	NULL
811	NULL
,	NULL
631-685	NULL
.	NULL

Deleted	NULL
in	NULL
proof	NULL
.	NULL

Mangelsdorf	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Umesono	NULL
,	NULL
K.	NULL
,	NULL
Kliewer	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
Borgmeyer	NULL
,	NULL
U.	NULL
,	NULL
Ong	NULL
,	NULL
E.	NULL
S.	NULL
,	NULL
and	NULL
Evans	NULL
,	NULL
R.	NULL
M.	NULL
(	NULL
1991	NULL
)	NULL
Cell	NULL
66	NULL
,	NULL
555-561	NULL
Rottman	NULL
,	NULL
J.	NULL
N.	NULL
,	NULL
Windom	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
Nadal-Ginard	NULL
,	NULL
B.	NULL
,	NULL
Mahadevi	NULL
,	NULL
V.	NULL
,	NULL
and	NULL
Karatha-nasis	NULL
,	NULL
S.	NULL
K.	NULL
(	NULL
1991	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

11	NULL
,	NULL
3814-3820	NULL
Zhang	NULL
,	NULL
X.-K.	NULL
,	NULL
Lehman	NULL
,	NULL
J.	NULL
,	NULL
Hoffman	NULL
,	NULL
B.	NULL
,	NULL
Dawson	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
Cameron	NULL
,	NULL
J.	NULL
,	NULL
Graupner	NULL
,	NULL
G.	NULL
,	NULL
Hermann	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Pfahl	NULL
,	NULL
M.	NULL
(	NULL
1992	NULL
)	NULL
Nature	NULL
858	NULL
,	NULL
587-591	NULL
Briggs	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
Kadonaga	NULL
,	NULL
J.	NULL
T.	NULL
,	NULL
Bell	NULL
,	NULL
S.	NULL
P.	NULL
,	NULL
and	NULL
Tjian	NULL
,	NULL
R.	NULL
(	NULL
1986	NULL
)	NULL
Science	NULL
284	NULL
,	NULL
47-52	NULL
Smith	NULL
,	NULL
K.	NULL
A	NULL
.	NULL

(	NULL
1984	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

2	NULL
,	NULL
819-333	NULL
Terada	NULL
,	NULL
N.	NULL
,	NULL
Takase	NULL
,	NULL
K.	NULL
,	NULL
Papst	NULL
,	NULL
P.	NULL
,	NULL
Nairn	NULL
,	NULL
A.	NULL
C.	NULL
,	NULL
and	NULL
Gelfand	NULL
,	NULL
E.	NULL
W.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

155	NULL
,	NULL
3418-3426	NULL
Hanauske-Abel	NULL
,	NULL
H.	NULL
M.	NULL
,	NULL
Park	NULL
,	NULL
H.	NULL
M.	NULL
,	NULL
Hanauske	NULL
,	NULL
A.	NULL
R.	NULL
,	NULL
Popowicz	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
La-lande	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Folke	NULL
,	NULL
J.	NULL
E.	NULL
(	NULL
1994	NULL
)	NULL
Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
1221	NULL
,	NULL
115-124	NULL
Marth	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Lewis	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
Wilson	NULL
,	NULL
C.	NULL
B.	NULL
,	NULL
Gearn	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
Krebs	NULL
,	NULL
E.	NULL
G.	NULL
,	NULL
and	NULL
Perlmutter	NULL
,	NULL
R.	NULL
M.	NULL
(	NULL
1987	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

6	NULL
,	NULL
2727-2734	NULL
Bhargava	NULL
,	NULL
A.	NULL
K.	NULL
,	NULL
Li	NULL
,	NULL
Z.	NULL
,	NULL
and	NULL
Weisman	NULL
,	NULL
S.	NULL
H.	NULL
(	NULL
1998	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

90	NULL
,	NULL
10260-10264	NULL
Prashar	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
Weissman	NULL
.	NULL

,	NULL
S.	NULL
H.	NULL
(	NULL
1996	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

98	NULL
,	NULL
659-663	NULL
Shaw	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Kamen	NULL
,	NULL
R.	NULL
(	NULL
1986	NULL
)	NULL
Cell	NULL
46	NULL
,	NULL
659-667	NULL
Makover	NULL
,	NULL
D.	NULL
,	NULL
Cuddy	NULL
,	NULL
M.	NULL
,	NULL
Yum	NULL
,	NULL
S.	NULL
,	NULL
Bradley	NULL
,	NULL
K.	NULL
,	NULL
Alpers	NULL
,	NULL
J.	NULL
,	NULL
Sukbatme	NULL
,	NULL
V.	NULL
,	NULL
and	NULL
Reed	NULL
,	NULL
J.	NULL
C.	NULL
(	NULL
1991	NULL
)	NULL
Oncogene	NULL
6	NULL
,	NULL
455-460	NULL
Kvanta	NULL
,	NULL
A.	NULL
,	NULL
Kontny	NULL
,	NULL
E.	NULL
,	NULL
Jondal	NULL
,	NULL
M.	NULL
,	NULL
Okret	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Fredholm	NULL
,	NULL
B	NULL
.	NULL

B	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Cell	NULL
.	NULL

Signalling	NULL
4	NULL
,	NULL
257-260	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
Activation-induced	NULL
Down-regulation	NULL
of	NULL
Retinoid	NULL
Receptor	NULL
RXRQ	NULL
Expression	NULL
in	NULL
Human	NULL
T	NULL
Lymphocytes	NULL
:	NULL
ROLE	NULL
OF	NULL
CELL	NULL
CYCLE	NULL
REGULATION	NULL
Mohammad	NULL
Ishaq	NULL
,	NULL
Yi-Ming	NULL
Zhang	NULL
and	NULL
Ven	NULL
Natarajan	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

1998	NULL
,	NULL
273:21210-21216.	NULL
doi	NULL
:	NULL
10.1074/jb0.273.33.21210	NULL
Access	NULL
the	NULL
most	NULL
updated	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
http	NULL
:	NULL
/www.jbe.org/content/273/33/21210	NULL
Alerts	NULL
:	NULL
«	NULL
When	NULL
this	NULL
article	NULL
is	NULL
cited	NULL
«	NULL
When	NULL
a	NULL
correction	NULL
for	NULL
this	NULL
article	NULL
is	NULL
posted	NULL
Click	NULL
here	NULL
to	NULL
choose	NULL
from	NULL
all	NULL
of	NULL
JBC	NULL
's	NULL
e-mail	NULL
alerts	NULL
This	NULL
article	NULL
cites	NULL
40	NULL
references	NULL
,	NULL
16	NULL
of	NULL
which	NULL
can	NULL
be	NULL
accessed	NULL
free	NULL
at	NULL
http	NULL
:	NULL
//www	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL

